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 Abstract 
Periconceptional Treatment with Growth Hormone Alters Fetal Growth and 
Development in Sheep 
 
Jill Marie Koch 
 
 Altering the fetal environment can modify the composition or growth rate of 
the fetus, a concept known as fetal programming.  A majority of the research in 
this area has focused on intrauterine growth restriction (IUGR), which has been 
linked to adult diseases.  A few studies have attempted to ameliorate the 
negative effects of IUGR, by applying growth promoters late in gestation, and 
have only observed transient effects.  Our laboratory has previously shown that 
growth hormone (GH) treatment around the time of breeding alters the uterine 
environment early in gestation and results in larger lambs at birth.  Therefore 
there were three main objectives investigated in the current work, each 
encompassing a different period of gestation.  The first objective was to examine 
how a periconceptional injection of GH alters the uterine environment at the time 
of early embryonic development and if the trophectoderm to inner cell mass ratio 
is altered by treatment. The second objective was to determine how GH 
treatment may program nutrient transport in the placenta late in gestation.  The 
third objective was to examine how a periconceptional injection of GH alters fetal 
growth and development at birth and how the GH axis may be altered in lambs 
born to ewes treated with GH.  Periconceptional GH treatment altered the 
concentration of growth factors in uterine luminal fluid including TGF-ß1, insulin 
like growth factor-I and urea, but did not alter the ratio of trophectoderm to inner 
cell mass cells or the total number of blastomeres.  Treatment with GH appeared 
to alter the placental expression of some nutrient transporters during gestation.  
Periconceptional treatment with growth hormone appears to alter the uterine 
environment during embryonic development, programming the cells of the 
embryo to exhibit an altered physiology.  Periconceptional GH treatment 
increased lamb weight and abdominal girth.  Lambs born to ewes treated with 
GH also had an altered GH axis as determined by a reduced hepatic expression 
of both insulin like growth factor-I and growth hormone receptor at birth and an 
altered response to GH releasing hormone challenge at 100 days of age.  
Periconceptional GH appears to program embryonic cells which develop into a 
more efficient placenta allowing for an increase in nutrient availability, ultimately 
leading to larger lambs at birth with an altered composition and an altered growth 
hormone axis. 
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Literature Review 
Fetal Programming 
 Fetal programming is described as any environmental insult or stimulus 
that occurs during the development of key organs or tissues and results in long 
lasting or permanent physiological alterations of the offspring (Godfrey and 
Barker, 2000; Armitage et al., 2004).  The amount of data collected on fetal 
programming is vast and includes both retrospective studies in humans and 
prospective studies in animals.  The concept of fetal programming stems from 
the “Barker Hypothesis” which developed from the medical records of adults who 
were gestated during the Dutch famine.  During this period, daily caloric intake 
dropped as low as 580 calories (Ravelli et al., 1976).  The epidemiological data 
collected from these humans gestated during the Dutch famine linked low birth 
weight with several adult onset diseases.  More specifically, low caloric intake 
during early gestation was linked to hypertension, but limited caloric intake during 
late gestation has been linked to adult obesity and glucose intolerance (i.e., 
metabolic disorders; Barker, 1995; Ravelli et al., 1999; Ameritage et al., 2004).   
 Exposure to an insult or a stimulus that result in long lasting and 
permanent physiological alterations is a phenomenon known as programming 
(Godfrey & Barker, 2000).  The impact of the uterine environment on fetal growth 
and development is more specifically known as fetal programming.  The “fetal 
origins” hypothesis suggests fetal programming results in permanent alterations 
in the structure, physiology and metabolism of the offspring, which predisposes 
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them to adult onset diseases (Barker 1995; Godfrey & Barker 2000).  In fact, the 
use of animal models has allowed researchers to link a deleterious uterine 
environment during specific stages of fetal development to altered development 
and function (i.e., program) of the cardiovascular, respiratory, endocrine, 
reproductive, skeletal, immune and central nervous systems as well as the 
function of the kidneys and liver (Godfrey and Barker, 2000; Wu et al., 2004).   
 The influence of the uterine environment from ovulation through birth 
permanently impacts the development of the offspring, ultimately influencing the 
health of the adult.  It has been suggested that the offspring’s genotype 
contributes only 15% to the variation in birth weight, while maternal environment 
(i.e., nutrition available to the fetus) has double the influence at 30%.  The 
remaining 55% is influenced by other stimuli (i.e., maternal size and uterine 
environment; Nathanielsz, 2000).  Animal models can be utilized to assess the 
impact of an altered uterine environment both in vivo and ex vivo.  The use of 
animals allows critical assessment of the effect of uterine environment (i.e. 
secretion, timing and space) on embryonic development, fetal growth and 
ultimately postnatal life. 
Embryonic and Early Fetal Development 
Embryonic Development 
 In sheep, the oviduct is the sight of fertilization and as such it is 
responsible for providing the proper environmental conditions in which early 
embryonic development occurs.  For fertilization to occur, the gametes must first 
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be transported to the site of fertilization at the ampullary-isthmic junction.  Sperm 
travel from the site of deposition in the most exterior portion of the cervix to the 
ampullary-isthmic junction.  The cilia in the upper portion of the oviduct always 
beat toward the site of fertilization (toward the uterus) and move oocyte to the 
ampullary-isthmic junction.  However, the other parts of female reproductive tract 
are sensitive to the estrogen to progesterone ratio.  A high estrogen to 
progesterone ratio results in contraction of the female reproductive tract toward 
the site of fertilization while a low ratio stimulates oviductal contractions which 
move the zygote (i.e., fertilized oocyte) toward the uterus (Crisman et al., 1980). 
 The fertilized ovum starts as a single cell surrounded by a glycoprotein 
layer called the zona pelucida (Figure 1).  The first divisions of the embryo are 
synchronous and called cleavage divisions.  Cleavage divisions take place until 
the embryo becomes a morula.  In the sheep, the embryo enters the uterus in the 
morula stage on day four following mating (Figure 1; Spencer and Bazer, 2004; 
Spencer et al., 2004).  The cells of the morula will become one of two embryonic 
cell types in the blastocyst, either the inner cell mass or the trophectoderm.  The 
trophectoderm is a single layer of cells connected by gap junctions.  These cells 
form a barrier around the inner cell mass and allow for the formation of a fluid 
filled cavity called the blastocoele.  The trophectoderm develops into the chorion 
portion of the placenta.  The inner cell mass is a ball of cells located inside the 
trophectoderm.  The inner cell mass will develop later into the embryo proper and 
eventually the fetus and portions of the placenta.  Transition from a morula to a 
blastocyst takes place in the uterus and only requires about 48 hours (day six of 
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pregnancy).  The morula transforms into a compact morula with trophectoderm 
cells forming on the outside and inner cell mass cells on the inside.  As the 
blastocyst continues to develop a blastocoelic cavity forms.  Further development 
between days six and eight leads to the blastocyst hatching out of the zona 
pelucida (Spencer et al., 2004).  It is not until around day eleven that the embryo 
starts to elongate going from a round sphere to a more filamentous shape.  
Growth continues to increase dramatically as the size of the embryo goes from 
about 30 mm on day 12 to about 190 mm by day 16 (Spencer et al., 2004).  
Around day 12, the embryo starts to produce vast quantities of interferon τ.  
Interferon τ is considered to be one of the molecules secreted by the embryo that 
signals maternal recognition of pregnancy and is thought to be stimulated by 
proper histotrophic nutrition (Gray et al., 2000; Gray et al., 2002; Spenser and 
Bazer, 2004).  Prior to day 16, the trophectoderm of the embryo has only been 
loosely associated with the endometrium; however, around day 16 the embryo 
starts to adhere to the endometrium (Spencer and Bazer, 2004; Spencer et al., 
2004).  The lack of any permanent attachments until day 16 limits the nutrients 
available to the embryo to just those found in the lumen of the oviduct and the 
uterus (i.e., histotrophic nutrition).  
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FIGURE 1. Schematic demonstrating early embryonic cell division and growth 
from fertilization up to day 16 of pregnancy as well as the progesterone and 
estrogen profile during this period.  Redrawn from Spencer et al., 2004. 
Reproduction. 128:657-668. 
 
Oviduct Environmental Influence 
 The oviductal fluid contains vitamins, amino acids, carbohydrates 
(glucose, pyruvate and lactate) growth factors, enzymes and proteins (Gandolfi 
et al., 1989; Nancarrow and Hill, 1995; Buhi et al., 2000; Killian, 2004; Aguilar 
and Reyley, 2005).  The components of the oviductal fluid are similar to plasma 
with the exception of a few proteins secreted only by the oviduct.  For example, 
the concentration of some amino acids (methionine, leucine, phenylalanine, 
lysine, aspartic acid, glycine, alanine, taurine, tyrosine) are actually only 25% of 
that which is observed in plasma, while others (threonine, serine, ornithine) are 
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actually higher in oviductal fluid (Aguilar and Reyley, 2005).  Compared to other 
species, only a small list of growth factors have been detected in sheep oviductal 
fluid and include basic fibroblast growth factor, insulin-like growth factor binding 
proteins 3 and 4, insulin Iike growth factor-I and II, transforming growth factor α 
and ß and prostaglandins E2 and F2α (Aguilar and Reyley, 2005). 
 Oviductal fluid only contains one tenth the protein found in plasma and it 
comes from two sources.  The primary source is plasma which provides proteins 
like albumin, immunoglobulins and high density lipoproteins which are present in 
the oviduct at a constant concentration and make up approximately 95% of the 
total protein found in oviductal fluid (Gandolfi et al., 1989; Killian, 2004; Aguilar 
and Reyley, 2005).  The secondary source of protein are those produced and 
secreted by the epithelium that lines the oviduct.  In sheep, and most other 
mammals, a group of oviduct specific glycoproteins or “oviductins” are only 
synthesized by oviductal epithelium.  These glycoproteins contribute to the 
extracellular matrix of the embryo, the oviduct micro environment and interact 
with the zona pelucida (Gandolfi et al., 1989; Murray, 1993; Buhi et al., 2000).  
Estrogen stimulates the oviductal epithelial cells to synthesize and secrete 
oviductins such that they are high at estrus.  Not surprising, these proteins are 
secreted, coincident with the time in which an embryo would be present, from 
day two to four and dropping to undetectable levels on day four shortly after the 
embryo should enter the uterus (Sutton et al., 1986; Murray, 1993). 
 The importance of oviductal proteins is evident from a study on in vitro 
embryo development in which approximately 90% of single cell embryos co-
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cultured with oviduct somatic cells developed to at least the eight cell stage, 
while only 13% of those cultured without cells reached the same developmental 
stage (Gandolfi and Moor, 1987).  The type of somatic cell used for co-culture 
also impacted embryonic development.  Embryos co-cultured with either 
oviductal epithelium or fibroblasts did not appear to have altered growth from day 
zero (fertilization) to day three, but when transferred back into recipient females 
only 33% of those cultured with fibroblasts continued to develop compared to 
80% development in those cultured with oviductal epithelium (Gandolfi and Moor, 
1987).  Others have demonstrated that including the glycoprotein fraction of 
oviductal fluid decreases the number of in vitro fertilized embryos that go through 
the first cleavage division, but including it in culture media increased the number 
of cloned embryos which developed to the blastocyst stage, which may suggest 
that it is more influential for older embryos (Nancarrow and Hill, 1995).  These 
experiments are consistent with a role for the oviductal milieu in proper 
embryonic development and provide a physiological mechanism as to how 
alterations to the pregnant female very early in pregnancy may permanently alter 
the embryonic cells. 
Uterine Environmental Influences 
 The uterine environment can exert its influences through either 
histotrophic (oviductal and uterine fluid derived nutrients) or hematotrophic 
(maternal blood derived) nutrition and a gestational stage specific milieu is 
thought to be essential for normal conceptus growth and survival.  Collectively, 
these two nutrient sources play a major role in embryonic development, 
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attachment and placentation (Gray et al., 2001; Spencer and Bazer, 2004).  
Histotrophic nutrients are synthesized and secreted by the glandular epithelium 
of the uterus (i.e., uterine glands).  Secretion of historophic nutrients is regulated 
by maternal and embryonic hormones (progesterone, estrogen and interferon τ).  
The second source of nutrients is hematotrophic, which describes the transfer of 
nutrients from maternal blood into fetal blood and is altered mainly by changes in 
uterine and umbilical blood flow (i.e., as uterine blood flow increases the amount 
of hematotrophic nutrition increases; Gray et al., 2001; Spencer and Bazer, 
2004).  Histotrophic nutrients bathe the embryo in the uterus and consist of 
enzymes, growth factors, ions, cytokines, hormones, adhesion molecules and 
transport proteins (Spencer and Bazer, 2004; Igwebuike, 2006).  Different 
experimental models have been utilized to examine the effects of altered uterine 
environment on embryonic growth and development and include embryo transfer, 
advancing the uterine environment and blocking the histogenesis of uterine 
glands. 
 It has been understood for a least 50 years that transferring embryos in 
any species requires a relatively high degree of synchrony between the donor 
and recipient.  In the ewe, the embryo can tolerate uterine asynchrony up to a 
two day window.  This means that the synchrony of the recipient female and the 
donor embryos must be within two days, but for optimal embryonic survival the 
donor and recipient should be at the exact same day following estrus (Moore and 
Shelton, 1964; Rowson and Moor, 1966; Wimut and Sales, 1981; Ashworth and 
Bazer, 1989).  Extending the window of transfer from 48 to 72 hours in either 
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direction of the embryonic stage (an additional 24 hours in either direction) 
decreases the success of embryo transfer by about 65% (~8% survive when 
transferred at ± three days; Rowson and Moor, 1966).  Not only does the window 
of opportunity impact success rate, but the stage of embryonic development at 
the time of transfer impacts overall success rate.  A time-dependent increase 
was observed in that, as the age of the embryo increased the rate of survival 
increased independent of recipient synchronization within a 48 hour window 
(Moore and Shelton, 1964).  Similar results were found by Rowson and Moor 
(1966) in which day five embryos (morulas) transferred to day seven recipients 
had a lower survival rate than day nine embryos (blastocysts) transferred into a 
day eleven recipient.  Zygotes cultured for six days in control conditions, co-
cultured with granulosa cells, or cultured in synthetic oviductal fluid with or 
without serum, before being transferred back to day 6 recipients, demonstrated 
the effect of early environment on fetal growth and development.  Fetuses 
derived from granulosa cell co-culture were 14% heavier by day 61 of gestation 
and 18% larger compared to controls on day 125.  Those cultured with synthetic 
oviductal fluid plus serum were18% heavier, compared to those cultured without 
serum, by day 125.  There was also an increase in the calculated growth 
coefficient for the liver and heart for the co-culture and synthetic oviductal fluid 
plus serum compared to control cultures (Sinclair et al., 1999).  These results 
demonstrate that uterine environment is critical to survival and altering the 
uterine milieu can alter the natural growth curve and alter fetal development. 
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 Progesterone administration is one mechanism used to study the impact 
of the uterine environment on embryonic development.  Progesterone 
administration during early pregnancy has been found to advance the uterine 
environment and lead to altered embryonic growth.  Fetal growth was increased 
in ewes exposed to progesterone from days 1-3, 3-6 or 1-6 of gestation.  
Progesterone treatment starting on day one had the greatest impact on fetal 
growth in that both fetal mass and crown-rump length were increased (Kleeman 
et al., 1994).  Embryos transferred to a more advanced uterine environment were 
found to be 42% heavier at day 21 of gestation (Young et al., 1996).  When day 
three embryos were transferred to a uterine environment advanced by three days 
(i.e., day 6 environment), for three days, and then transferred back to a day six 
environment, the fetuses that developed had alterations in muscle development.  
While there was no difference in fetal weight or crown-rump length, those 
embryos transferred to an asynchronous environment had a greater number of 
muscle fibers compared to those maintained in a synchronous environment 
(Maxfield et al., 1998).  This indicates that only a small change in the embryonic 
environment, for a short amount of time, can result in “fetal programming.” 
Placental Anatomy 
 The placenta’s function is to provided a physiological exchange 
mechanism between the fetus and dam removing waste from the fetus, 
exchanging gas and providing nutrients for proper fetal growth.  The sheep 
placenta has two general regions 1) placentomal region and 2) interplacentomal 
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regions (Igwebuike, 2006).  The placentomes are areas in which cotyledonary 
villi (fetal placenta) penetrate deep into the caruncular tissue (maternal 
attachment points) creating areas for hematotrophic nutrition, as well as gas and 
waste exchange (Figure 2; Reynolds et al., 2005a).  These villi are lined with 
microvilli that increase surface area for nutrient absorption.  Placental growth is 
exponential from establishment (approximately day 24) with the number of 
possible placentomes between 60 and 100 per placenta being determined by day 
56 of gestation (Renyonlds et al., 2005; Igwebuike, 2006).  The placenta, 
primarily cotyledonary tissue, will continue to proliferate until about day 80 going 
from 15 g at day 40 to 770 g at day 80 of gestation when the mass of the 
placenta dramatically declines (441g day 100), but angiogenesis increases 
exponentially (Ehdart and Bell, 1995).  Placental weight has been correlated with 
fetal development late in gestation in that 80% of the variation in fetal weight can 
be accounted for by variation in placental weight which may indicate that a poorly 
developed placenta results in a poorly developed fetus (Bell et al., 1999). 
 As gestation progresses and fetal nutrient demand increases placentome 
morphology changes to meet these needs.  Placentomes are characterized into 
four different groups (A, B, C and D type) based on cotyledonary tissue growth.  
Type A are spherical placentomes in which the fetal cotyledonary tissue is 
completely surrounded by maternal caruncular tissue and are concave in the 
middle (cotyledonary tissues is sunken into the middle of caruncular tissue).  
Type B placentomes can be described as those in which fetal tissue is starting to 
grow over top of the maternal caruncular tissue.  Type C placentomes are flat on 
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top (cotyledonary tissue has completely filled the caruncle) and cotyledonary 
tissue only completely covers one surface of the caruncle which means that the 
sides of the caruncle are still visible.  Type D placentomes are flat and everted.  
Fetal cotyledonary tissue is completely covering the top and sides of the 
maternal caruncular tissue (Osgerby, et al., 2004; Vonnahme et al., 2006) 
 Ruminants, including the sheep and cow, have the least intimate contact 
between maternal and fetal circulation with six tissues layers between the 
maternal and fetal circulations and this occurs in the area of the placentome 
which makes up approximately 95% of the total interactive surface area 
(Wooding et al., 2005).  These layers consist of three layers on the maternal side 
including endothelium, stroma and epithelium (syncytium) and three fetal layers 
including epithelium (trophoblast cells), stroma and fetal endothelium (Figure 2; 
Bjorkman, 1965).  This type of placentation is called epitheliochorial because 
there are two complete and intact layers of epithelium.  It is important to note that 
sheep can have only five layers, in this instance the maternal epithelium is 
transiently eroded, which can regrow, but it leaves short periods of time when the 
maternal epithelium is fused with fetal epithelium.  As a result sheep are 
sometimes known as having a syndesmochorial placenta (Reynolds et al., 
2005a). 
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FIGURE 2. Schematic of the sheep placentome including caruncular and 
cotyledonary tissue layers.  The arrows indicate blood flow. (Redrawn from 
Senger, PL. 1999. 2nd Edition Pathways to Pregnancy and Parturition).  The 
second portion of the schematic includes a close up of the six tissue layers in the 
epithelialchorial placenta of the sheep. 
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Placental Vasculature 
 In sheep, placental growth (in terms of weight) slows dramatically around 
day 80 of gestation yet nutrient delivery and transport must keep up with 
demands of the developing fetus.  Under normal pregnancy conditions, umbilical 
blood flow, oxygen transport and water transport all increase faster than fetal 
weight as a way to compensate for growth of the fetus and lack of growth by the 
placenta (i.e., extraction rate of nutrients increases; Reyonlds and Redmer, 
1995).  A more influential mechanism to keep up with the exponential growth of 
the fetus is a three to four fold increase in uterine blood flow between mid to late 
gestation, which results in an increase in the amount of nutrients available for 
extraction (Rosenfeld et al., 1974). 
 Concurrent with the dramatic increase in blood flow is an increase in 
angiogenesis of the placentome.  The number of vascular changes in the 
maternal caruncular tissue is relatively small compared to vascular growth of fetal 
cotyledonary tissue, but both have an increase in angiogenesis (Table 1; 
Reynolds et al., 2005a; Reynolds et al., 2005b).  Capillary area density, capillary 
number density and capillary surface area all increase between day 50 and 140 
of gestation in both maternal and fetal tissue (Table 1; Reynolds et al., 2005a; 
Reynolds et al, 2005b).  The major difference between maternal and fetal 
circulation in the placenta is the type of vessels found.  Maternal vessels are 
larger, with less surface area and are indicative of vessels that have slower 
velocity to increase time for extraction by the placenta.  Fetal cotyledonary 
vessels on the other hand are smaller, with small branching architecture, which is 
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best utilized in systems with high velocity to allow for quick nutrient absorption 
(Reynolds and Redmer, 1995; Reynolds et al., 2005a).  These alterations in 
blood flow and the capillary networks compensate for the limited growth of the 
placenta in the second half of gestation by increasing the extraction efficiency of 
the placenta.  Increasing placental efficiency by vascular adaptations is further 
demonstrated by using carunclectomized sheep.  In this model a portion of 
caruncles are removed from the uterus of the ewe limiting the number of 
placentomes that can be formed.  Late in gestation, uterine and fetal blood flow 
and placental size are decreased when compared to intact controls, leading to 
restricted fetal growth.  It is speculated that the limited transport of nutrients 
results from a reduction in the capillary surface area (as a result of reduced 
placentome number) required for nutrient exchange (Robinson et al., 1995).  In 
some circumstances the limited number of placentomes that do exist undergo 
extensive proliferation and are able to provide a greater area for nutrient 
exchange than observed in placentomes of intact controls allowing for normal 
fetal growth (Robinson et al., 1995).  
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 Capillary 
Area Density
Capillary No. 
Density 
Capillary 
Surface 
Density 
Area per 
Capillary 
Fetal 
(Cotyledonary) 
6.2x 12.3x 6.0x (-)1.9x 
Maternal 
(Caruncular) 
3.3x 1.5x 1.7x 2.2x 
 
TABLE 1. Maternal (caruncular) and fetal (cotyledonary) angiogenic changes that 
occur between day 50 and 140 of gestation.  All measures increase except for 
area per capillary in cotyledonary tissue (Reynolds et al., 2005a). 
 
Nutrient Transporters 
 Nutrients have to be in sufficient supply and delivered to the developing 
fetus in a timely fashion for proper growth and development.  In the last third of 
gestation, a period in which fetal growth increases exponentially, limiting fetal 
nutrient availability has been directly linked to intrauterine growth restriction and 
long term alterations in organ function.  The mechanisms by which this occurs 
includes a decrease in maternally derived nutrients or insufficient transport of 
nutrients across the placenta (Barker 1995; Ravelli et al. 1999; Godfrey & Barker 
2000; Jensen et al. 2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al. 
2005; Wu et al. 2006).  Until recently, investigators have suggested that limiting 
nutrient availability was the cause of fetal growth restriction; however, recently 
some have argued that if the number of transporters are limited, no matter what 
the nutrient availability intrauterine growth restriction occurs (Jansson et al., 
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2006).  There are several mechanisms utilized to transport nutrients across the 
placenta and include facilitated diffusion, passive transport down a concentration 
gradient, and endocytosis.  
Glucose Transporters 
 Glucose is essential to the fetus because it is the primary substrate for 
fetal energy metabolism and is obtained from maternal circulation via placental 
transport (Robertson and Karp, 1976; Jansson et al., 1993; Bell et al. 1999).  
Under normal gestational conditions, in which the dam is well-nourished, glucose 
accounts for approximately 60% of the net uptake of carbon to the gravid uterine 
horn and transport increases five to eight fold in the last third of gestation 
(Jansson et al. 1993; Carver and Hay 1995; Chung et al. 1998; Bell et al. 1999; 
Dandrea et al. 2001).  Glucose appears to be passively transferred to the fetus 
by a concentration-dependent mechanism as the transporters identified are all 
sodium independent (Limesand et al., 2004; Wooding et al., 2005).  Because 
glucose is passively transferred to the fetus, maternal glucose concentration has 
to remain higher than fetal glucose concentrations (Hay, 1995).  This 
concentration gradient is maintained by two mechanisms.  The first is an 
increasing rate of consumption by the growing fetus and placenta clearing fetal 
blood of glucose and the second is maternal development of glucose tolerance 
and insulin resistance raising blood glucose concentrations in maternal blood. 
 Glucose transporter 1 (GLUT-1) glucose transporter-3 (GLUT-3; both are 
sodium independent) and glucose transporter 8 (GLUT-8; sodium dependent) are 
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the only glucose transporters that have been identified in the sheep placenta.  
Total placental mRNA expression and protein abundance of GLUT-1 and GLUT-
3 increase with an increase in the demand for glucose by the fetus.  The greatest 
expression and abundance for GLUT-1 varies with the number of fetuses and the 
technique used to analyze mRNA.  Currie and coworkers (1997) utilized PCR 
and reported that GLUT-1 expression peaked at day 60 of gestation, whilel 
Ehrhardt and Bell (1997) used northern blotting and reported an increase in 
GLUT-1 expression increases from day 75 to 140 in twin pregnancies (Ehrhardt 
and Bell, 1997).  However, both expression and protein abundance for GLUT-3 
increased from day 60 till term.  Approximately 86% of all glucose binding sites 
on day 75 are predicted to be GLUT-1 but by day 140 this drops to only 56% 
(Ehrhardt and Bell, 1997).  Glucose transporter-3 and not GLUT-1 transports the 
majority of glucose required by the fetus at the end of gestation.  The shift to 
primarily GLUT-3 transport may be a result of a decrease in glucose binding to 
GLUT-1 as well as a reduction in both mRNA and protein.  Glucose transporter 8 
also increased as gestation progressed (Limesand et al., 2004).  The increased 
capacity of the placenta to transport glucose appears to be a function of three 
things.  First is an increase in the total amount of transporter.  Second, the 
increase in capillary density and thereby total surface area leading to a much 
greater increase in the total number of glucose transporters beyond a simple 
increase in relative expression.  Third the increase in the concentration gradient 
that occurs in the last third of gestation (Molina et al., 1991; Hay, 1995). 
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 Glucose transporter-1 has been found on the basal and apical surface of 
the fetal epithelium (trophoblast; Das et al., 2000; Wooding et al., 2005).  The 
localization of GLUT-3 has been detected on the apical surface of the 
trophectoderm (Das et al., 2000; Wooding et al., 2005).  Glucose transporter-8 
has only been localized to the chorionic epithelium without a specific membrane 
border given (Limesand et al., 2004).  It has been speculated that because of the 
differential localization of these isoforms, glucose must utilize different isoforms 
sequentially to be able to pass from maternal circulation to fetal circulation in 
sheep to meet the glucose demands of the growing fetus. 
Amino Acid Transporters 
 Amino acids are the building blocks of all proteins, including those proteins 
synthesized in utero by the developing fetus and placenta.  The essential amino 
acids are not synthesized, but extracted from maternal circulation and 
transported to fetal circulation, via placental amino acid transporters (Cetin, 2001; 
Kudo and Boyd, 2002).  Therefore, alterations in placental amino acid transporter 
number or transporter function may lead to intrauterine growth restricted fetuses.  
On the opposite side an increase in the functionality of these transporters may 
allow for an increase in the amino acid concentration in fetal circulation leading to 
an increase in fetal growth and development. 
 Amino acid transporters have been classified into many different 
categories based on ion-dependence, substrate specificity, kinetics, the type of 
amino acid transported (i.e., neutral, anionic, cationic, branched chain or 
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aromatic) and possible interactions with an additional subunit (Table 2; Jansson, 
2001; Kudo and Boyd, 2002; Regnault et al., 2005).  Amino acid transporters do 
not specifically transport just one amino acid, but transport amino acids with 
similar structural characteristics (Kudo and Boyd, 2002).  This also means that 
net amino acid transport in any direction (maternal to fetal or fetal to maternal) 
may require the use of more than one amino acid transport system.  Amino acid 
transporters are located in all cell types throughout the body, but not all of these 
amino acid transporters have been identified in the placenta and the majority of 
information known about location of amino acid transporters in placental tissue is 
limited mainly to human and rodent species.  The human has a hemochorial 
placenta in which maternal blood bathes the fetal trophoblast while the rodent 
has a hemoendothelial in which maternal blood bathes the fetal endothelium.  
The trophoblast in this instance is the barrier for amino acid transport, but in the 
sheep, amino acids would have to cross both maternal and fetal epithelia and 
endothelia before entering fetal circulation.  The table provided below 
summarizes the type of transporters known in human placenta and includes the 
system type, the gene, substrates moved by the transporter membrane, location 
in human fetal trophoblast cells and the type of transporter. 
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TABLE 2. Amino acid transporter systems, gene name, amino acids transported, 
the location of transported in fetal trophoblast cells in the human and the type of 
transport system. 
 
Placental Efficiency 
 Placental efficiency is defined as the grams of fetus that can be supported 
by each gram of placenta and is calculated simply as fetal weight divided by its 
placental weight.  The size of the placenta and more specifically the surface area 
available for nutrient exchange impacts placental efficiency.  When placental 
weight is used as a crude measure for total placental contact (meaning the larger 
the placenta the greater likelihood for surface area contacts) it is positively 
correlated to body weight (Fowden et al., 2006).  However, the efficiency of the 
placenta is more important and it is those placentas that fall above he trend line 
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reflects placenta that are the most efficient meaning they produce the greater 
amount of fetal weight with a smaller placental weight.  In sheep average birth 
weight of twins and triplets is approximately 80% (4.4 kg) and 70% (3.6 kg) of a 
singleton lambs (5.4 kg).  The number of placentomes is reduced by 
approximately 40% per twin and approximately 75% per triplet compared to a 
singleton fetus (total placentome mass 0.7 kg), but the placenta is able to change 
and compensate for the lack of nutrient exchange areas (Gootwine et al., 2007).  
Placental efficiency and the ability of the placenta to compensate has also been 
examined under experimental conditions, including uterine ligation and nutrient 
restriction. 
 Uterine ligation limits pregnancy to only one uterine horn limiting the 
number of caruncles available to form placentomes (Bazer et al., 1979; Caton et 
al., 1984; Ott et al., 1997).  Uterine ligation results in a reduction in placentome 
number between 23% and 50%.  In experiments when the total number of 
placentomes was reduced 50%, by day 140 of gestation fetal weight, placental 
weight and cotyledonary weight were reduced (Caton et al., 1984).  However, in 
experiments in which only a 23% reduction in placentome number was observed 
in uterine ligated animals, there was no difference in fetal size (crown-rump 
length or weight), total placentome weight or placentome weight to fetal weight 
ratios.  In fact, individual placentome weight increased by 27% in ligated animals 
which was mainly a result of an increase in the cotyledonary portion (Ott et al., 
1997). 
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 Limiting maternal nutrition limits nutrients available to the fetus.  In 
extreme conditions, such as a 50% reduction in nutrient intake, the placenta 
compensates by increasing placentome size (specifically the cotyledonary 
portion) and therefore increasing the surface area available for exchange.  These 
experiments further demonstrate that the placenta has the ability to become 
more efficient when fetal nutrient demand increases.  When pregnant ewes were 
restricted to 50% of control diet, the type of placentomes that developed 
indicated that an increase in angiogenesis had occurred, as a means of 
attempting to compensate for nutrient restriction.  On day 78 of gestation, after 
50 days of restriction, the majority of placentomes in control ewes were of the A 
type, while the nutrient restricted group had a larger proportion of the B, C and D 
type placentomes (Vonnahme et al., 2006).  In this experiment, placental 
efficiency was not different between nutrient restricted and control ewes.  The 
placentas ability to compensate for poor nutrition is further demonstrated utilizing 
the undernourished adolescent ewe model.  Maintaining pregnancy during a time 
of maternal growth and development depletes maternal body stores and adding 
nutrient restriction, further limits nutrients available to the fetus.  On day 90, 
under these extreme circumstances, total placentome weight, mean placentome 
weight and gross anatomy were not different between control and nutrient 
restricted.  By day 130 of gestation, there was a modest reduction in fetal weight.  
Only a modest reduction in fetal weight compared to the expected extreme 
reduction may be a result of placental compensation.  The placental parameters 
were not different and similar changes in placentome type from mostly A type 
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placentomes to a mix of A, B, C and D type placentomes had occurred by day 
130.  It was further noted that cotyledonary capillary density increased which 
increases vessel surface area and cotyledonary number density increased as 
gestation advanced while caruncular capillary density decreased (Luther et al., 
2007).  The authors noted that fetal growth was restricted in the nutrient 
restriction group; however, it was speculated that fetal development would have 
been further perturbed without proliferation of the cotyledonary capillaries (Luther 
et al., 2007).   
Somatotrophic Axis 
Fetal Growth Axis 
 Growth hormone (i.e., somatotropin) is detected as early as day 43 and is 
at least 20 times higher in concentration in fetal circulation compared to that 
observed in adults and is secreted in a biphasic pattern (Stokes and Boda, 1968; 
Basset and Gluckman, 1986; Polkowska et al., 1995).  The concentration of 
growth hormone is high between day 60-70 of gestation (148 ng/ml) falling to 49 
ng/ml by day 100 through 110 and reaching a second peak concentration of 150 
ng/ml between day 130 and 140 (Gluckman et al., 1979a).  However, growth 
hormone concentration drops 80% within one hour of birth such that neonatal 
growth hormone concentration plummets to less than 10 ng/ml (Gluckman et al., 
1979a; Bassett and Gluckman, 1985).  The regulation of fetal growth hormone 
secretion is not known, but is believed to be, in some part, regulated by the 
somatotrophic axis.  Growth hormone synthesis and secretion in the fetus is 
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regulated by growth-hormone-releasing hormone and somatostatin, but the 
regulation of the secretion of these two hormones in the fetus is not yet known.  
Both hormones are synthesized in the hypothalamus and detectable by mid 
gestation in the sheep (Polkowska et al., 1995).  Growth-hormone-releasing 
hormone administration to the fetus results in an increase in growth hormone 
secretion (De Zeghner et al., 1989).  Somatostatin inhibits the release of growth 
hormone when administered to the fetus and removal of somatostatin allows for 
growth hormone to rise (Gluckaman 1979b).  While growth hormone secretion is 
regulated during fetal development it does not stimulate fetal growth because it 
does not appear to stimulate insulin like growth factors (IGF) which are the major 
hormones responsible for stimulating fetal growth.  Growth hormone is present 
but the receptor is expressed at very low levels until right before birth (stimulated 
by the glucocorticoid surge; Gluckman and Pinal, 2003). 
 Insulin like growth factor-I is the predominant growth factor late in 
gestation that stimulates growth along with IGF II, and both are produced by the 
fetal liver and other tissues during fetal development (Lok et al., 1996).  Both 
IGF-I and IGF-II elicit a growth response by binding to the IGF-I receptor.  Insulin 
like growth factor-II receptor is a clearance receptor decreasing the concentration 
of IGF-ll in circulation but binding does not elicit a response (Gluckman and 
Pinal, 2003).  In fact, birth weight and crown-rump length are highly correlated to 
IGF-I (Bauer et al., 1998).  During gestation the main regulator of IGF-I is glucose 
availability (Oliver et al., 1996).  Nutrients detected in fetal blood obtained after a 
four hour infusion of IGF-I around day 130 of gestation suggest fetal growth is 
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promoted.  Insulin like growth factor-I infusion resulted in a decrease in fetal 
amino acid nitrogen concentrations, a trend for an increase in amino nitrogen 
uptake and a decrease in fetal urea production (a measure of amino acid 
oxidation) which all suggest an increase in fetal growth (Harding et al., 1994).  In 
a similar study in which fetal infusion of IGF-I occurred from day 120 to 130 of 
gestation an increase in internal organ weights were observed in treated fetuses.  
There was an increase in the weight of the liver, heart, kidney, and spleen and an 
increase in length of some of the long bones, but no observed difference in 
muscle weight (Lok et al., 1996). 
Postnatal Growth Axis 
 Unlike what is observed during fetal development, growth hormone 
regulates the secretion of IGF-I and is therefore the hormone that stimulates 
postnatal growth (Gluckman et al., 1986).  Growth hormone secretion is 
regulated by growth hormone releasing hormone, somatostatin and partially by 
ghrelin.  Growth hormone releasing hormone stimulates both synthesis and 
secretion of growth hormone while, somatostatin inhibits secretion but not 
synthesis.  Ghrelin which is produced by the stomach, intestine and central 
nervous systems has also been found to stimulate the synthesis and secretion of 
growth hormone at the level of the hypothalamus and pituitary (Gluckman et al., 
1986; Anderson et al., 2004).  In sheep, growth hormone secretion is 
asynchronous and episodic and the pulse patterns are different between males 
and females.  A higher pulse amplitude and higher baseline are typical 
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characteristic for a male pattern compared to lower amplitudes with a lower 
baseline level for females (Gatford et al., 1997). 
 Insulin like growth factor-I (i.e., somatomedin C) and IGF-II (i.e., 
somatomedin A) are produced throughout the body with the liver being the main 
source.  Their secretion is stimulated by growth hormone, other hormones and 
other substances (i.e., insulin, steroids, interleukins and amino acids).  Insulin 
like growth factor-I is the more potent growth stimulator and promotes growth in 
both a paracrine and endocrine manner (Douglas et al., 1991).  Insulin like 
growth factors bind to insulin like growth factor binding proteins in the blood, 
which act as a storage mechanism since free IGF-I is not stored in any organ or 
tissue.  The concentration of total IGF-I in plasma is 100 to 1000 mg/ml which is 
well above what is required to elicit a response, but this includes all IGF-I (bound 
and free; Gluckman et al., 1987).  In sheep, fetal levels of IGF-I are similar to 
those observed in the adult (120 ng/ml).  However, at birth IGF-I concentrations 
rapidly increase to about 400 ng/ml and remain elevated until about day 50, at 
which time they decrease to around adult levels.  Insulin like growth factor-II on 
the other hand drops dramatically the last five days of gestation to the levels 
observed at birth (795 ng/ml to 160 ng/ml) and remains at about the same level 
from birth through adulthood (Gluckman and Butler, 1983). 
Intrauterine Growth Restriction 
 Since the original link was made between birth weight and adult onset 
disease, the fetal origins of adult disease has been extensively examined using 
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animal models.  Several animal models have been developed to study fetal 
programming, utilizing maternal dietary manipulation, hyperthermia, hormone 
administration, uterine artery ligation and embolization of the placenta to 
establish a detrimental uterine environment (Wallace et al., 2001; Jensen et al. 
2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al. 2005; Wu et al., 2006).  
Dietary manipulation to the dam has been the most widely used experimental 
paradigm for investigating programming.  The specific regimens for applying 
dietary restriction are numerous, as the specific details and duration of dietary 
restrictions used are numerous (Wu et al., 2004; Wu et al., 2006; Wallace et al., 
2005).  The majority of fetal growth restriction models work by inducing placental 
insufficiency.  The link between altered placental growth, vascular development, 
nutrient transport, placental metabolism and the partitioning of nutrients between 
the dam and the fetus are all speculated to impact programming of the fetus and 
adult adaptation to the environment. 
 The majority of fetal programming/intrauterine growth restriction studies 
have been developed and performed in rodents, most likely a result of cost and 
availability.  However, a few models utilizing the ewe have been developed and 
extensively studied.  The ovine is one species that is utilized as an animal model 
for humans for a few reasons.  First, they normally only have singles or twins 
compared to pigs and rodents that have larger litters.  Second, nutrient restriction 
alters nutrient availability to the fetus.  In pigs, the dam has the remarkable ability 
to mobilize maternal body stores to compensate for nutrient intake.  In fact, a 
moderate restriction does not result in intrauterine growth restriction (Wu et al., 
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2006).  Third, a lamb fetus is large enough to instrument allowing for collection of 
data from a fetus in a conscious female.  These models include the nutrient 
restriction, overnourished adolescent ewe, maternal heat stress and placental 
embolization. 
Maternal Nutrient Restriction 
 Nutrition is speculated to be the major factor influencing placental and 
fetal growth and development.  As a result, maternal nutrition plays a critical role 
in proper development of the placenta and therefore nutrient availability to the 
developing fetus.  Evidence suggesting such a strong role for the effects of 
maternal nutrition is found naturally and experimentally.  Range animals are 
subjected to forages which are affected by seasonal climate change and severe 
weather.  In the western United States, ewes are maintained on less than 50% of 
the daily nutrients recommended by the National Research Council.  Lambs that 
were born to ewes that were exposed to these harsh conditions appeared to 
have compromised health (Thomas and Kott, 1993; Vonnahme et al., 2003; Wu 
et al., 2004).  Nutrient restriction in experimental models can vary in the severity, 
duration and period of pregnancy (i.e., early, mid or late gestation) of the 
restriction. 
 The majority of maternal nutrient restriction models impose restriction 
between day 28 and 80 of gestation.  Some nutrient restrictions are extend for 
longer periods of time, until fetal tissue collection (day 90 or 135).  The level of 
nutrient restriction is highly variable and ranges from 30% to 50% of the daily 
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nutrient requirement.  Fetal weight is reduced approximately 32% by maternal 
nutrient restriction from day 28 to day 80 regardless of the level of nutrient 
restriction (30% or 50%; Vonnahme et al., 2003; Kwon et al., 2004;).  However, 
others have observed that nutrient restriction did not have an effect on lamb 
weight at term (Heasman et al., 1998; Ford et al., 2007).  When nutrient 
restriction was extended to gestational day 135 only a 15% reduction in fetal 
weight was observed (Osgerby et al., 2002; Kwon et al., 2004; Osgerby et al., 
2004).   
 Surprisingly, even though nutrient restriction was applied during the time 
in which the placenta is undergoing rapid growth to day 78, no difference in 
placental weight was observed (Vonnahme et al., 2003).  However, by term total 
placental weight, as well as fetal cotyledonary tissue weight was greater in the 
treated group compared to the controls.  This increase in weight may be 
associated with a decrease in the number of A type placentomes and an 
increase in the number of B and C type placentomes observed at term (Heasman 
et al., 1998; Osgerby et al., 2004).  Information available on umbilical blood flows 
are variable in that some research shows an increase while others show no 
change (Reynolds et al., 2005).  Nutrient flux across the placenta appears to be 
altered by nutrient restriction during early and mid gestation in the ewe.  Glucose 
concentration and 11 of 23 amino acids measured in fetal circulation were 
decreased in fetuses gestated by ewes subjected to a nutrient restriction 
compared to those gestated by controls (Osgerby et al., 2002; Kwon et al., 
2004).  Maternal nutrient restriction appears to alter placental function early in 
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gestation which results in limited fetal growth.  However, upon removal of the 
restriction the placenta appears to compensate by its altering growth.   
Overnourished Adolescent Ewe Model 
 The overnourished adolescent ewe model utilizes the hierarchy of nutrient 
partitioning to limit fetal placental growth.  Normally, nutrition is shunted to the 
fetus to promote proper growth, but when the dam is still growing (i.e., 
adolescent) maternal growth takes priority above fetal growth which means 
nutrients are partitioned to maternal growth at the cost of the gravid uterus.  The 
majority of the reduction in fetal and placental weight comes from altered nutrient 
partitioning.  Overfed growing adolescents gain at least four times as much 
weight (200-350 g/day) compared to those fed a moderate diet (50-85 g/day).  
The increase in weight comes from an increase in fat storage and maternal body 
weight gain (Wallace et al., 2006b).  The results of these studies show a 
reduction of 33% in the overall feto-placental mass at birth compared to 
moderately fed controls which correlates to a 29% reduction in birth weight 
(Wallace et al., 2001).  Fetuses from overnourished ewes are normally small for 
their gestational age and born premature. 
 Overnourishing adolescent ewes reduces uterine blood flow and placental 
function which limits nutrient availability to the developing fetus and results in 
small lambs at birth.  Nutrients available for transport are reduced as a result of a 
decrease in uterine blood flow by approximately 36% compared to control.  When 
fetal weight is taken into consideration the uterine blood flow is proportionally the 
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same, but umbilical blood flow per gram of fetal weight is reduced by 15% which 
is consistent with the suggestion that uterine blood flow regulates fetal growth 
(Wallace et al., 2002b).  In this model established placentomes not only have a 
smaller mass, but the actual number established per placenta is reduced 
compared to moderately fed controls (Wallace et al., 2001).  Overnourishing 
adolescent pregnant ewes reduced umbilical amino-acid uptake for 12 of 16 
amino acids measured and glucose.  The decreased uptake was speculated to 
result from a reduction in placentome total surface area because when placental 
uptake was expressed on a placental weight basis, no difference in glucose 
uptake was observed (Wallace et al., 2002a; Wallace et al., 2004).  The 
reduction in fetal weight, placental weight and nutrient transfer may be a result of 
a reduction in angiogenesis within the placenta or uterine blood flow.  On day 81, 
(the point when placental growth reaches a plateau but angiogenesis continues 
to compensate for the continual rapid growth of the fetus) expression of 
angiogenic factors including vascular endothelial growth factor, angiopoietin 1, 
angiopoietin 2 and nitric oxide synthase 3 were decreased by almost 50% in 
overnourished adolescent ewes compared to those that were moderately fed 
(Redmer et al., 2005). 
Maternal Heat Stress Model 
 In sheep, increasing the external ambient temperature 20 degrees during 
the middle to final portion of pregnancy results in placental insufficiency and poor 
fetal development.  The general procedure is to place ewes in a hot room around 
day 35 of gestation, the time when the rapid growth phase of the placenta starts, 
 33 
and remove the ewes approximately 60 days later.  The duration of exposure to 
high temperature per day varies among experiments and ranges from only nine 
hours per day to a constant 24 hour per day exposure.  High ambient 
temperatures were considered 40°C compared to controls, 18-20°C, and the 
humidity ranged from 30-40% (Thureen et al., 1992; Galan et al., 1999; Bell et 
al., 2003).  During periods of heat exposure, ewe rectal temperature averages 
about 40.3°C which is one degree higher than those housed at control 
temperatures (Bell et al., 1989).  Exposing a pregnant ewe to extreme ambient 
temperature reduces fetal weight in a time-dependent manner.  In all cases, high 
ambient temperature exposure resulted in a reduction of at least 17% to 50% in 
fetal body weight compared to those fetuses collected from ewes housed in a 
thermoneutral temperature. 
 A 54% reduction in placental weight was observed following exposure to 
extreme ambient temperature which is most likely a result of a decrease in 
placentome weight (Bell et al., 1989; Thureen et al., 1992).  Uterine blood flow is 
not different in pregnant ewes subjected to either a thermoneutral or 
hyperthermic environment; however, when scaled to either fetal or placental 
weight (uterine blood flow/weight) uterine blood flow is increased in those ewes 
exposed to higher ambient temperatures suggesting that uterine blood flow is not 
reduced in relationship to metabolic demands of the placenta and fetus (Thureen 
et al., 1992; Regnault et al., 2003).  Nutrient delivery via uterine blood flow may 
not be limiting but, a reduction in umbilical blood flow may be the cause for a 
decrease in nutrient extraction.  Heat stress led to a reduction in fetal glucose 
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concentration, fetal uptake of glucose and overall extraction of glucose by the 
gravid uterus (Regnault et al., 2003).  Heat stressed pregnant ewes exhibited 
altered placental expression of angiongenic factors.  In maternal caruncular 
tissue of heat stressed ewes, expression as well as protein concentration of 
placental growth factor (PlGF) increased, but no changes were observed for 
vascular endothelial growth factors.  In fetal cotyledonary tissue, vascular 
endothelial growth factor expression and protein decreased, PlGF was not 
altered by hyperthermic conditions (Regnault et al., 2003).  In this model, the 
maternal supply of nutrients appears not to be limiting fetal growth, but a limited 
growth and development of the fetal side of the placenta appears to be the 
culprit. 
Placental Embolization 
 Placental embolization is used to study the fetal growth axis in growth 
restricted fetuses late in gestation.  Around day 110 of gestation, pregnant ewes 
undergo surgery to place catheters in the maternal uterine artery and to 
chronically catheterize the fetus.  Around two days post surgery microspheres 
between 25 and 50 µm in size are injected into the maternal artery catheters 
twice daily for two days.  The duration and amount of microspheres injected daily 
is then altered based on fetal growth (as measured by a growth catheter placed 
around the chest of the fetus) and when fetal growth is slowed or stopped for two 
days then embolization is stopped.  Injection of microspheres creates a placental 
insufficiency limiting blood flow to the placenta and limits the area available for 
nutrient exchange.  In all cases, embolism resulted in a reduction in fetal weight 
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ranging from 15% to 38% (Jensen et al., 1999; Bloomfield et al., 2002; Bauer et 
al., 2003; Louey et al., 2005).  In the only study that measured placental weight, 
embolization led to a 30% reduction in placental weight at birth (Louey et al., 
2005).  Alterations in placental weight are of limited value, since the majority of 
placental growth is during the first 80 days of gestation.  However, it is not 
surprising that placental weight decreased because it requires nutrients from 
maternal blood to meet its metabolic demands. 
Impact of Intrauterine Growth Restriction 
 The above described models create forms of placental insufficiency and 
altered nutrient delivery which may lead to temporary or permanent alterations in 
fetal organ development and function.  In intrauterine growth restricted fetuses, 
blood is shunted to the brain at the expense of other organs including the heart 
and liver.  In humans, for example, the reduced abdominal circumference 
observed in intrauterine growth restriction may be an indicator of reduced liver 
growth and development.  In fact, smaller abdominal circumference at birth has 
been correlated with elevated concentrations of total and low density lipoproteins, 
cholesterol and fibrinogen in the blood, which are risk factors for adult 
cardiovascular disease.  Barker et al. (1995) utilized abdominal girth as way to 
assess liver development and found that small abdominal circumference at birth 
was correlated with an increased incidence of coronary heart disease regardless 
of social status, weight, smoking or alcohol consumption.  Below is a table that 
summarizes general outcomes observed with different models of fetal growth 
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restriction.  Included are measures of fetal development and organ weights 
relative to fetal body weight and how they are impacted by models of intrauterine 
growth restriction (Table 3). 
 The data presented in the table are summarized from a number of studies 
and therefore, variation in the general summary may be a result of the exact 
protocol used to induced fetal growth restriction.  All of the studies led to a 
reduced fetal size as measured by fetal weight, crown-rump length and 
abdominal girth.  However, the information available on fetal organ growth is 
limited and sometimes contradictory.  For example, maternal under nutrition 
appears to have no effect on abdominal girth at day 78 of gestation but 
abdominal girth is reduced by day 135 (Osgerby et al., 2002; Vonnahme et al., 
2003).  Similarly, liver weight relative to fetal weight is increased at day 78 but no 
difference is observed by day 135.  Data may be influenced by the duration and 
timing of nutrient restriction.  Until day 78, fetal growth is very slow while 
placental growth is quite rapid.  However, data collected on day 135 is influenced 
by continual nutrient restriction through the placental growth phase and through 
the rapid fetal growth phase.  Heart weight and ventricular wall thickness may be 
harder to explain because it has been speculated that heart development is 
affected by other vascular measures.  Fetuses gestated by dams, nutritionally 
restricted to 50% of the control group from day 28 to day 78 of gestation, had an 
increased ventricular weight per gram of fetal body weight (Vonnahme et al. 
2003).  A hypertrophic increase in the fetal ventricular wall has been suggested 
to result from an increase in ventricular afterload which is indicative of an 
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increase in peripheral arterial pressure (Samson et al. 2000; Vonnahme et al. 
2003).  A mechanism by which placental vascular resistance may result in 
altered fetal heart development has been postulated by Vonnahme et al. (2003).  
In sheep, intrauterine growth restriction can lead to an increased placental 
vascular resistance (Vonnahme et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
Maternal Nutrient Restriction 
     Fetal Weight ▼ at all stages of gestation 
     Crown-rump Length ▼ at all stages of gestation 
     Abdominal Girth 
No Change at day 78 of gestation (period of placental 
growth) 
▼ by day 135 of gestation (during the period of rapid fetal 
growth) 
     Brain Weight No Change 
     Liver Weight 
▲ at day 78 of gestation (period of shunted placental   
growth) 
No difference by day 135 (placenta is able to compensate 
and increase nutrient flux to the developing fetus increasing 
liver growth) 
     Heart Weight 
▲ Right and left ventricular wall weight at day 78 of 
gestation 
▼ in total heart weight at day 135 
Overnourished Adolescent Ewe 
     Fetal Weight ▼ during fetal development and at birth 
     Crown-rump Length ▼ during fetal development  
     Abdominal Girth ▼ during fetal development 
     Brain Weight No change in two out of three studies (one study found an 
increase) 
     Liver Weight No change  
     Heart Weight No change 
Maternal Heat Stress 
     Fetal Weight ▼ during fetal development 
     Crown-rump Length 
No difference was observed when heat stress was applied 
early in gestation  
▼ when heat stress was induced around the time of rapid 
fetal growth 
     Brain Weight No change in two out of three studies (one study found an increase) 
     Liver Weight 
No difference was observed in two out of three studies (the 
one study that detected a decrease started applying heat 
stress late in gestation  
     Heart Weight No change 
Placental Embolization 
     Fetal Weight ▼ following embolization 
     Crown-rump Length ▼ following embolization  
     Abdominal Girth ▼ following embolization 
     Brain Weight No change 
     Liver Weight No change was observed in two out of three studies but one of three observed a reduction in fetal liver weight 
     Heart Weight 
No change was found in two of four studies 
▼ in heart weight in two out of four studies 
▼ Right and left ventricular wall thickness 
TABLE 3. Impact of nutrient restriction models on fetal components and organ 
weights. 
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Statement of the Problem 
 The use of animal models has allowed extensive investigation in the field 
of fetal programming, specifically critical assessment of the effect of uterine 
environment (i.e. secretion, timing and space) on embryonic development, fetal 
growth and ultimately adult life.  Using animals models, researchers have been 
able to link a deleterious uterine environment during specific stages of fetal 
development to altered development and function (i.e., programming) of the 
cardiovascular, respiratory, endocrine, reproductive, immune and central nervous 
systems as well as the function of the kidneys and liver and bone density 
(Godfrey and Barker, 2000; Wu et al., 2004).  However, the majority of studies 
conducted in the area of fetal programming have been limited to only the effects 
of a negative uterine environment.  Few studies have tried to ameliorate the 
impact of experimentally induced intrauterine growth restriction by administering 
growth promoters, but again the basis of the experiment is to first inhibit fetal 
growth.  However, the growth that is stimulated is only transient. 
 Therefore, we endeavored to investigate a recent observation from our 
laboratory that reported that a single injection of growth hormone given at 
breeding results in lambs that are ~10% larger at birth (Costine et al., 2005).  
Determining how a single injection of growth hormone at breeding promotes 
growth throughout gestation leading to heavier lambs 145 days later may 
ultimately change how we think about fetal programming.  The present studies 
were designed to specifically address three important questions.  First, how is the 
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early uterine environment altered by a single injection of growth hormone given 
that this environment can potentially program the developing embryo?  Second, 
how does the placenta that develops from the conceptus exposed to an altered 
uterine environment become more efficient and able to transport more nutrients 
to the developing fetus late in gestation when fetal demand for nutrients 
increases?  Third, do lambs born to ewes treated with growth hormone, have 
altered growth and development, including programmed alterations of the growth 
hormone axis of the lambs born to ewes treated with growth hormone? 
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Abstract 
 We have shown that an injection of sustained release growth hormone 
(GH), given just prior to breeding, results in lambs that are 10% heavier at birth, 
with an altered body composition as evidenced by an increased abdominal girth, 
but no difference in crown-rump length.  The mechanisms by which these 
differences occur from a single periconceptional injection are not yet known.  
Therefore, the objective of this experiment was to determine the effect of an 
injection of GH given prior to breeding on the composition of the uterine 
environment at the time of blastocyst formation and the trophectoderm to inner 
cell mass ratio.  Ewes were synchronized with two injections of prostaglandin 
given eight days apart.  On the day of the second injection, ewes were randomly 
assigned to be given an injection of sustained release GH or remain as controls 
and penned with a ram.  On day 6.5 following breeding embryos were surgically 
collected by flushing each oviduct.  Prior to surgery a jugular blood sample was 
taken to determine plasma progesterone and urea concentrations.  The uterine 
content of urea, prostaglandin F2α, prostaglandin E2, transforming growth factor 
ß-1 (TGF ß), nitric oxide metabolites and total protein were measured.  Collected 
embryos were differentially stained to calculate a trophectoderm to inner cell 
mass ratio.  The uterine content of urea in the GH group was lower (p < 0.05) 
than that of the control group.  There was a trend for TGF ß to be increased in 
the GH treated group compared to control (p=0.07).  There was no difference in 
the total uterine content of prostaglandin F2α, prostaglandin E2, protein or nitric 
oxide metabolites.  The concentration of progesterone and insulin in maternal 
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plasma was greater in the treated group compare to controls, but blood urea 
nitrogen was not different between groups.  The trophectoderm to inner cell mass 
ratio or the total number of blastomeres was not different between treatment 
groups.  Thus, we suggest that the observed difference in fetal development 
following periconceptional growth hormone administration just prior to breeding 
may be a result of an alteration in the uterine environment, which may alter the 
cellular program of the conceptus and later development, beyond the embryonic 
stage. 
Key Words: growth hormone, uterine environment, embryo 
 44 
Introduction 
 Exposure to an insult or a stimulus during critical periods of development 
can result in long lasting and possibly permanent physiological alterations, a 
phenomenon known as programming (Godfrey & Barker, 2000).  The uterine 
environment in which the conceptus and developing fetus are exposed to has 
been extensively studied.  Particularly in the sheep, studies range from the 
effects of early uterine environment through late gestational treatments.  
However, the majority of these studies focus on negatively impacting fetal growth 
and development and only a limited number of studies have tried to promote fetal 
growth and development. 
 It has been understood for at least 50 years that altering the early 
embryonic environment can greatly impact embryonic growth and survival 
(Moore and Shelton, 1964).  The success of embryo transfer drops below 10% if 
the embryos are transferred to a uterine environment that is more than 48 hours 
ahead or behind that from which the embryo was collected (Rowson and Moor, 
1966).  The stage of embryonic development also impacts the success of 
embryonic survival as a time-dependent increase.  Specifically as the age of the 
embryo increased the rate of survival increased (Moore and Shelton, 1964; 
Rowson and Moor 1966).   
 Embryo transfer into an advanced uterine environment has been found to 
alter early fetal development (Kleeman et al., 1994; Young et al., 1996).  Fetal 
growth was increased in ewes exposed to progesterone during the first six days 
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of gestation (Kleeman et al., 1994).  Similarly, Young et al. (1996) found that 
fetuses derived from embryos transferred to an advanced uterine environment 
were 42% heavier by gestational day 21.  Recently, we demonstrated that a 
single injection of growth hormone given at or just prior to breeding increases 
birth weight by 10 (Costine et al., 2005). 
 Therefore, the objective of this experiment was to determine the effect of 
an injection of sustained release growth hormone given just prior to breeding on 
the composition of the uterine environment at the time of blastocyst formation.  
Additionally the ratio of trophectoderm to inner cell mass is altered and the total 
number of blastomeres was determined to possible alterations in embryonic 
growth.  
 
Materials and Methods 
 Ewes (n=59), primarily of Suffolk breeding, from the West Virginia 
University farm were used for the experiment.  All procedures were approved by 
the West Virginia University Animal Care and Use Committee (ACUC No. 05-
0805).   
 Estrus was synchronized by administering two injections of 20 mg (i.m.) of 
prostaglandin F2α (Lutalyse, Pfizer; New York, NY) eight days apart.  Ewes were 
randomly assigned to either a control group (n=35) or a growth hormone treated 
group (n=24).  The growth hormone treated group received a single 500 mg 
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injection of sustained release recombinant bovine growth hormone 
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the same time as the 
second prostaglandin F2α injection.  This dose was previously reported to 
increase uterine luminal insulin like growth factor-I (IGF-I) 4-fold on day 7 of 
gestation and result in larger lambs at birth (Costine et al., 2005).  Ewes were 
penned with a fertile ram fitted with a marking harness and ewes were checked 
twice daily for the appearance of new marks which occurred two to three days 
(day 0) following the second prostaglandin F2α injection.   
 
Embryo Collection 
 On day 6.5, ewes underwent surgery for embryo collection.  Briefly, all 
ewes were anesthetized and maintained on a 10% ketamine drip (Vedco; 
Columbus Serum, Columbus, OH) and 50 mg/ml sodium pentobarbital to effect 
(Sigma; St. Louis, MO).  A midventral incision was made in the abdominal wall to 
expose the uterus and the oviducts.  The right and left uterine horn were flushed 
separately as follows.  A small incision was made at the base of the uterine horn 
and a glass cannula was inserted into uterine horn.  A blunted needle, attached 
to a glass syringe, was inserted into the oviduct through the infundibulum.  
Pinching off around the needle, 10 ml of phosphate buffered saline (pH 7.4) was 
flushed through the oviduct and uterine horn to the glass cannula and collected in 
petri dish.  Embryos were removed from the flushings and processed for 
immunosurgical lysis.  Flushings were centrifuged at 2,000 x g to pellet any 
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cellular debris and the remaining flushing was aliquoted into microcentrifuge 
tubes and stored at -20°C until further analysis. 
 
Immunosurgical Lysis 
 Immnunosurgical lysis allows for the differential staining of the two main 
cell types of the blastocyst, the trophectoderm and the inner cell mass.  Embryos 
were stained using a procedure previously used to stain pig embryos but 
modified to allow for proper staining of sheep embryos (Rivera et al., 1996).  
Embryos were incubated in Tyrode’s Solution (0.8% NaCl, 0.4% polyvinyl 
pyrrolidone, 0.24% CaCl2·H2O, 0.1% glucose, 0.02% KCl, and 0.01% 
MgCl2·6H2O; pH 2.5) for 45 s at 39°C to remove the zona pellucida.  Embryos 
were then rinsed three times in modified phosphate buffered saline (mPBS; 1% 
penicillin-streptomycin, 0.4% BSA, 0.0036% sodium pyruvate and 0.0023% L-
glutamine).  Embryos were then incubated with 10 nmol/L trinitrobenzene 
sulfonic acid (Sigma, St. Louis, MO) for 30 min on ice.  Trinitrobenzene sulfonic 
acid labels the surface of the trophectoderm cells with trinitrophenol groups.  
Embryos were then washed three times in mPBS and then placed in 0.1 mg/ml 
anti-dinitrophenol (Sigma, St. Louis, MO) for 30 min at 39°C.  Anti-dintrophenol is 
antiserum against dintrophenol and cross reacts with trinitrophenol groups which 
form on the surface of the trophectoderm following exposure to trinitrobenzene.  
Embryos were then washed three times in mPBS and placed into a mPBS 
solution containing a 1:5 dilution of guinea-pig complement (Sigma, St. Louis, 
MO) and 0.01mg/ml propidium iodide (Sigma, St. Louis, MO) for 30 min at 39°C 
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in the dark.  Guinea pig complement interacts with the antibodies attached to the 
trophectodermal cells and lyses the trophectoderm cells allowing propidium 
iodide into the cell.  The nuclei of these cells are thus stained red.  Embryos were 
then washed two times in mPBS before being incubated for 15 min in the dark at 
39°C in 0.05 mmol/L Hoechst 33258 in mPBS (Sigma; St. Louis, MO).  After 15 
min embryos were moved into a 0.05 mmol/L Hoechst 33258 in 100% ethanol 
protected from light and incubated overnight at 4°C.  Hoechst can cross all 
membranes and stains nuclei blue.  Therefore, the nuclei of the inner cell mass 
appear blue, and the nuclei of the trophectoderm appear pink because they are 
stained with both propidium iodide and Hoechst (Figure 3).  Embryos were then 
incubated in 100% ethanol for 30 mins at 4°C.  Following fixation in ethanol 
embryos were transferred to a slide with 5 µl of glycerol and covered with a glass 
cover slip.   
 The number of inner cell mass and trophectoderm cells for each embryo 
(n=27 control, n=17 GH) were counted using an inverted microscope (Nikon 
TE2000) equipped with a mercury vapor lamb and a UV filter set which 
illuminated the embryo at 380 nm, which is the wave length of excitation for both 
dyes and a barrier filter at 420 nm.  The two types of nuclei were counted by two 
different counters independently and these numbers were averaged together.  
The total number of cells was calculated by adding all the red and blue cells 
together. 
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FIGURE 3. Differential staining of a blastocyst collected on day 6.5 by 
immunosurgical lysis.  The inner cell mass cells are stained blue while the 
trophectoderm is stained pink. 
 
 
Uterine Flushings 
Prostaglandins 
 Prostaglandin E2 and prostaglandin F2α were analyzed by commercially 
available EIA (Cayman Chemical Company; Ann Arbor, MI) and validated in our 
laboratory to detect prostaglandins in uterine flushing.   
TGFβ-1 
 The TGFβ-1 in the uterine flushings was determined using a human 
TGFβ-1 Duo Set enzyme linked immuno-sorbent assay (ELISA) kit (R&D 
Systems, Minneapolis, MN) and ELAST® ELISA amplification system 
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(PerkinElmer Life Sciences, Boston, MA) following manufacturers’ instructions 
and altered for uterine flushings (Holaskova, 2007).  Briefly, flat bottom 96 well 
Nunc-Immuno plates with MaxiSorp surface treatment (Fisher Scientific, PA), 
were coated with capture antibody (mouse anti- TGFβ-1; 2 µg/mL) and incubated 
overnight at room temperature.  After a wash, plates were blocked by adding the 
blocking buffer for a minimum of 1 hour, washed, and 100 µl of acid-treated 
uterine flushing (1N HCl for TGFβ-1 activation, 1.2 N NaOH/0.5 M HEPES for 
neutralization), or standards were added in duplicate.  An eight-point standard 
curve consisted of 2-fold serial dilutions of recombinant human TGFβ-1, starting 
at 125 pg/mL for the high stanard.  Plates were incubated overnight at 4°C, 
washed, and the detection antibody was applied (biotinylated chicken anti-human 
TGFβ-1, 300 ng/mL) for 2 hours at room temperature.  Streptavidin conjugated to 
horseradish peroxidase was added to each well, incubated for 20 min at room 
temperature in the dark, washed, and was followed by substrate solution (H2O2 
mixed 1:1 with tetramethylbenzidine, R&D Systems, Minneapolis, MN) for 20 min 
at room temperature in the dark.  A biotinyl-tyramide amplification step was 
inserted into the ELISA procedure (ELAST® ELISA Amplification System; Perkin 
Elmer, Boston, MA), which increased the sensitivity to 2 pg/mL.  The reaction 
was stopped with 2 N H2SO4 (50 µL/well) and plates were analyzed with a 
microplate spectrophotometer (SPECTRAmax® PLUS384,Molecular Devices, 
Sunnyvale, CA).  Readings at 540 nm were subtracted from those at 450 nm for 
the wavelength correction, and plotted against the standard curve using the 
SoftMax®Pro software (version 4.6, Molecular Devices, Sunnyvale, CA).  The 
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unknown fluid validation protocol resulted in detection of 82% of recombinant 
TGFβ-1 in the uterine flushing samples.  Duplicate values with less than a 20% 
coefficient of variation were accepted for statistical analysis. 
Urea 
 The urea concentration in uterine flushing and maternal plasma were 
determined by a commercial assay kit for measuring urea in biological samples 
(BioAssay Systems; Hayward, CA).  Duplicate values with less than a 20% 
coefficient of variation were accepted for statistical analysis. 
Nitric Oxide Metabolites 
 One way of assessing nitric oxide production is to measure its two 
metabolites nitrite (NO2-) and nitrate (NO3-).  Nitrite in uterine flushing was 
determined using a commercially available assay (Griess Reagent System; 
Promega; Madison, WI).  The concentration of nitrite and nitrate in uterine 
flushing was subsequently determined using a commercial assay kit in biological 
samples (BioAssay Systems; Hayward, CA) in which nitrate is reduced to nitrite 
and total nitrite is determined.   
Protein 
 The Bradford assay was used to determine protein content in uterine 
flushing.  A standard curve was generated using BSA (Pierce, Rockford, IL) and 
Coomassie blue dye (Pierce, Rockford, IL), which upon binding to protein 
changes absorbance from 465 nm to 598 nm.  The absorbance at 598 nm is 
directly proportional to the amount of protein in the sample.  Duplicate values 
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with less than a 20% of coefficient of variation were accepted for statistical 
analysis. 
Maternal Plasma 
Progesterone 
 Progesterone concentrations from jugular plasma samples were 
determined using RIA (Sheffel et al., 1982) with a sensitivity of 100 pg/ml and 
intra- and interassay CV of 4.3 and 7.7%, respectively. 
Insulin 
 Jugular plasma insulin was measured using an insulin RIA kit (Diagnostic 
Products Corporation, Los Angeles, CA) with a sensitivity of 0.05 nM and 
intraassay CV of 3.1%.  The assay was validated to measure sheep insulin in our 
laboratory.  Briefly, plasma dilutions from two ewes were assayed separately for 
insulin and found to be parallel with the standard curve (Lemley et al., 2008a) 
 
Statistical Analysis 
 The effect of periconceptional growth hormone treatment to the dam on 
the concentration of protein, urea, prostaglandin E2, prostaglandin F2α, TGF ß1 
in uterine flushings was analyzed by analysis of variance, utilizing the general 
linear models procedure in SAS.  The effect of periconceptional growth hormone 
treatment on maternal progesterone concentration was analyzed by analysis of 
variance, utilizing the general linear models procedure in SAS.  The correlation 
 53 
between trophecoderm to inner cell mass ratio and uterine flushing components 
was determined using the correlation procedures of SAS. 
 
Results 
 Periconceptional GH treatment increased maternal progesterone (p < 
0.05; Figure 4) and insulin (p < 0.05; Figure 5) concentrations.  However, GH 
treatment did not alter maternal blood urea nitrogen (51.03 ± 3.11 mg/ml). 
 Periconceptional growth hormone treatment did decrease uterine luminal 
urea (p < 0.05) content on day 6.5 of pregnancy (Figure 6).  There was a trend 
for an increase in TGF-ß1 (p = 0.07; Figure 7).  Growth hormone treatment did 
not alter uterine content of prostaglandin F2α (1677.02 ± 97.23 ng/ml), 
prostaglandin E2 (763.48 ± ng/ml), nitrite and nitrate (86.35 ± 4.11 µM) or nitrite 
(7.39 ± 0.41 µM).  Overall GH treatment did not alter the trophectoderm to inner 
cell mass ratio (4.26 ± 0.60) or the total number of blastomeres per embryo 
(40.38 ± 3.37). 
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FIGURE 4. Maternal progesterone concentration on day 6.5 of gestation in 
control ewes and those treated with a periconceptional GH injection.  * Indicates 
a treatment difference p < 0.05. 
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FIGURE 5. Maternal insulin concentration on day 6.5 of gestation in control ewes 
and those treated with a periconceptional GH injection.  * Indicates a treatment 
difference p < 0.05. 
   * 
 56 
U
re
a 
C
on
te
nt
, m
g/
m
l
10
15
20
25
30
Control
Growth Hormone
*
 
FIGURE 6. Uterine luminal urea content on day 6.5 of gestation in control ewes 
and those treated with a periconceptional GH injection.  * Indicates a treatment 
difference p < 0.05. 
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FIGURE 7. Uterine luminal TGFß-1 content on day 6.5 of gestation in control 
ewes and those treated with a periconceptional GH injection.  * Indicates a 
treatment difference of p < 0.05. 
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Discussion 
 The concentration of progesterone and insulin in the GH treated group 
were greater than the concentration observed in the control group.  Progesterone 
administration is one tool used to study the impact of the uterine environment on 
embryonic development.  Progesterone treatment during early pregnancy has 
been shown to increase both fetal mass and crown-rump length later in 
gestation.  Fetal growth was increased in ewes exposed to progesterone from 
days 1-3, 3-6 or 1-6 of gestation (Kleemann et al., 1994).  Progesterone 
treatment starting on day one had the greatest impact on fetal growth in that both 
fetal mass and crown-rump length increased (Kleemann et al., 1994).  
Progesterone exposure on only days 3-6 increased fetal mass, but not to the 
extent of that observed when treatment was started on day one, and fetal crown-
rump length was not different (Kleeman et al., 1994).  Embryos transferred into a 
recipient uterine environment on day 3, which was previously primed by 
progesterone administration starting on days 1-3, had approximately 7% greater 
fetal mass on day 76 compared to control fetuses (Kleemann et al., 1994).  Day 3 
embryos transferred to a more advanced uterine environment on (i.e., a day 6 
uterine environment) for three days before being transferred back into their 
original uterine environment (i.e., now a day 6) were found to be 42% heavier at 
day 21 of gestation (Young et al., 1996).  Maxfield et al. (1998) utilized the same 
transfer methods in which day three embryos were transferred to a uterine 
environment advanced by three days (i.e., day 6 environment), for three days, 
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and then transferred back to a day six environment.  The fetuses collected from 
this experiment had altered muscle development.  While there was no difference 
in fetal weight or crown-rump length, those embryos transferred to an 
asynchronous environment had a greater number of muscle fibers compared 
tothose maintained in the synchronous environment (Maxfield et al., 1998).  This 
indicates that only a small change in the embryonic environment, for a short time, 
can result in “fetal programming.”   
 The observed elevation in progesterone concentrations in ewes treated 
with growth hormone may be explained by an increase in production of 
progesterone, a decrease in catabolism of progesterone or a combination of 
both.  Recent studies in the ewe and dairy cow have shown an inverse 
relationship with insulin and progesterone catabolic enzymes.  In this study 
growth hormone treatment resulted in increased peripheral concentrations of 
insulin and progesterone, those ewes treated with growth hormone probably had 
alterations in progesterone catabolism.  Progesterone is converted into 21-
hydroxyporgesteron or 6ß-hydroxyprogesterone via hepatic cytochrome P450 2C 
and 3A, respectively (Murray 1991, 1992).  Smith et al., (2006) found that 
anestrus ewes had decreased progesterone clearance when orally gavaged with 
propionate, a gluconeogenic substrate that stimulates insulin secretion in 
ruminants.  Ewes supplemented with sodium propionate had elevated insulin 
concentrations and a 45% reduction in hepatic cytochrome P450 2C and 3A 
activity at 1 hour after feeding compared to an energy control group (Lemley et 
al., 2008a).  Progesterone catabolism may be altered acutely by a reduction in 
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cytochrome P450 activity during hepatic exposure to elevated insulin 
concentrations.  Lemley et al., (2008b) found that dairy cows chronically exposed 
to a hyperinsulinemic-euglycemic clamp had a dose-dependent descrease in 
hepatic cytochrome P450 2C and 3A mRNA expression versus insulin dosage.   
 In the current experiment, no difference was observed in the total number 
of blastomeres or the trophectoderm to inner cell mass ratio even though lambs 
born to ewes treated with a periconceptional injection of GH are approximately 
10% larger at birth (Costine et al., 2005).  It may not be surprising that no 
difference was found considering that progesterone treatment from days 1-3 
advanced embryonic development as measured by the number of blastomeres 
per embryo on day 3 (Kleemann et al., 1994).  In a similar study in which 
progesterone was administered from day 4-9 of gestation, no difference was 
found in conceptus development on day 10 (Ashworth and Bazer, 1989). 
 Histotrophic nutrients bathe the embryo in the uterus and consist of 
enzymes, growth factors, ions, cytokines, hormones, adhesion molecules and 
transport proteins (Spencer and Bazer, 2004; Aguilar and Reyley, 2005; 
Igwebuike, 2006).  In this study, TGFß-1 was elevated in uterine flushings of 
ewes treated with a periconceptional injection of GH.  Previously, our laboratory 
reported that periconceptional injection of GH increased IGF-I in a dose 
dependent manner on day 7 (Costine et al., 2005).  Growth factors play an 
important role in embryonic and fetal growth and appear to be differentially 
secreted into a uterine environment from the time an embryo is a single cell 
through term (Watson et al., 1994).  In particular, IGF-I is known to be the most 
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important fetal growth promoter and is correlated with birth weight and crown-
rump length (Bauer et al., 1998).  Further investigation into other growth factors 
that are secreted by the oviductal and uterine epithelium that are differentially 
expressed in response to a periconceptional GH injection may provide additional 
insight into what factors program embryonic cells leading to a more efficient 
placenta and larger lambs at birth.  
 In the current experiment, the concentration of urea was decreased in 
uterine flushing in those animals treated with a periconceptional injection of GH.  
This finding may be a result of changes in amino acid metabolism.  Growth 
hormone can stimulate the accretion of protein which would lead to a reduction in 
amino acid oxidation and overall less urea production.  The increase in amino 
acid utilization may be from an increase in uterine gland secretion or production 
of other uterine proteins.  While urea may not directly program the embryo, it may 
be correlated with a reduction in the overall amino acids in circulation and in 
uterine flushings.  Unfortunately the methods used in this experiment to collect 
embryos diluted uterine flushings by 20 ml and made it difficult to detect amino 
acids.   
 In conclusion, periconceptional GH administration appears to alter some 
aspects of uterine environment which may be mediated through an increase in 
maternal progesterone, but further investigation into changes in uterine 
environment following periconceptional GH treatment is required.  The changes 
that were observed did not appear to alter embryonic growth as determined by 
total cell number or trophectoderm to inner cell mass ratio.  Future studies should 
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investigate the possible mechanisms in which programming of the embryo occurs 
leading to an increased placental efficiency and larger lambs at birth as a result 
of a single periconceptional growth hormone treatment. 
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Abstract 
 Fetal growth is limited by the ability of the placenta to provide the proper 
nutrients required for growth, including glucose, which is the primary source of 
energy and amino acids which are required for protein accretion.  These nutrients 
move from maternal circulation to fetal circulation by a variety of nutrient 
transporters.  We have demonstrated that sustained release growth hormone 
(GH) given to ewes at breeding increases placental efficiency and birth weight.  
The objective of this experiment was to determine if GH at breeding alters the 
expression of placental nutrient transporters, including glucose transporters 
(GLUT)-1 and -3, as well as amino acid transporters EAAT-1, EAAT-3, LAT-1, 
LAT-2, CAT-1 and SNAT-2.  Ewes were mated at estrus and half of the ewes 
were given 500 mg of sustained release GH at the time of breeding.  On days 80 
and 140 of gestation an umbilical blood sample and cotyledonary tissue were 
collected.  The RNA from cotyledonary tissue was extracted and used to 
determine the expression of nutrient transporters by real-time RT-PCR.  
Treatment with GH did not alter the expression of GLUT-1 or GLUT-3; however, 
GLUT-3 expression increased from day 80 to 140 of gestation.  There was a 
treatment by day interaction for both EAAT-1 and EAAT-3.  Expression in the 
controls increased from day 80 to 140 of gestation, but those in the GH group 
had similar expression on day 80 and 140 of gestation which was similar to 
controls on day 140.  Treatment did not alter the expression of LAT-2, CAT-1 and 
SNAT-2, however, expression increased from day 80 to 140 of gestation.  There 
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was no effect of treatment or day on the expression of LAT-1.  A positive 
correlation was observed between fetal size as measured by fetal weight, with 
GLUT-3, EAAT-3 and SNAT-2.  A positive correlation was also observed 
between crown-rump length, and EAAT-3 and LAT-1.  The increase in live weight 
observed in lambs born to ewes treated with GH at breeding may be a result of 
increased uptake of amino acids transported by EAAT’s from maternal 
circulation, which are essential for protein accretion.  This may be one reason 
why lambs born to ewes treated with growth hormone are larger at birth. 
Key Words: Growth Hormone, Glucose Transporters, Amino Acid Transporters 
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Introduction 
 Nutrients need to be delivered in sufficient supply to the developing fetus 
in a timely fashion for proper growth and development.  In the last third of 
gestation, a period in which fetal growth increases exponentially, limiting fetal 
nutrient availability has been directly linked to intrauterine growth restriction and 
long term alterations in organ function.  Until recently, investigators have 
suggested that limiting nutrient availability was the cause of fetal growth 
restriction; however, some have argued that if the number of transporters are 
limited, no matter what the nutrient availability, intrauterine growth restriction 
occurs (Jansson et al., 2006).  Therefore, the efficiency of the placenta may play 
a major role in the developmental potential of the fetus. 
 Nutrients, including glucose and amino acids, are shuttled from maternal 
to fetal circulation by specific transporters.  Both GLUT-1 and GLUT-3 are 
present in placental tissue and expression increases for both transporters until 
about mid gestation, but GLUT-3 expression continues to increase till term 
(Currie et al., 1997; Ehrhardt and Bell, 1997).  Several amino acid transporter 
families have been identified in placental tissue; including those in the A, ASC, 
B0, X-AG, b0,+, L and y+.  These systems work together to transport amino acids 
across epithelial layers of both the maternal and fetal placenta.   
 Previously, our laboratory demonstrated that growth hormone (GH) 
administered at breeding alters both fetal and placental growth (Costine et al., 
2005).  Lambs are at least 10% heavier at birth and the weight difference is 
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maintained when reared as singles.  The placental growth pattern in GH treated 
ewes is dramatically altered in that placental growth does not plateau at 
midgestation but instead growth is linear.  As a result of this altered growth 
pattern placentae of in the growth hormone group are more efficient (fetal weight/ 
chorioallantoic weight) compared to controls (Costine et al., 2005).  Therefore the 
objective of the current experiment was to determine if GH treatment at the time 
of breeding alters the expression of nutrient transporters in cotyledonary tissue. 
 
Materials and Methods 
 Ewes, of mixed breeding, from the West Virginia University farm were 
used for the experiment.  All procedures were approved by the West Virginia 
University Animal Care and Use Committee (03-1012).  
 The cotyledonary tissue and fetal samples utilized in this experiment were 
collected previously by Costine et al. (2005).  Briefly, ewes were randomly 
assigned to either a control group or a GH treated group.  The GH treated group 
received a single 500 mg injection of sustained release recombinant bovine GH 
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the time of mating.  On 
day 80 or 140 of gestation dams were euthanized with a lethal injection of 
sodium pentobarbital (Sigma; St.  Louis, MO) and the pregnant uterus was 
removed.  The fetuses were removed from the uterus and fetal body weight and 
crown-rump length were determined (Costine et al., 2005).  Cotyledons were 
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physically removed from caruncular tissue.  The cotyledonary tissue was snap 
frozen and stored at -80°C until further analysis. 
Real-Time RT PCR 
 Placental RNA was extracted using TRIzol as described by Koch et al. 
(2007).  This procedure includes two back extractions against acid 
phenol:chloroform (5:1; pH=4.5; Ambion, Austin, TX) followed by two back 
extractions against phenol:chloroform: isoamyl alcohol (25:24:1; pH=6.6) to 
remove additional proteins, DNA and lipids.  The RNA was reconstituted in 30 µl 
of nuclease free water and the concentration was determined 
spectrophotometrically at 260 nm.  The quality of RNA was determined by the 
appearance of bands corresponding to 28S and 18S rRNA and a distribution of 
mRNA of high molecular weight on a 3% agarose gel with ethidium bromide.  
Complementary DNA (cDNA) was synthesized from 2 µg of RNA which was 
reverse transcribed using random hexamers and Moloney Murine Leukaemia 
Virus reverse transcriptase (Promega, Madison, WI).  Real-Time RT PCR 
(iCycler, Bio-Rad Laboratories, Hercules, CA) was utilized to quantify the 
abundance of cDNA as previously described (Koch et al., 2007).  Primers 
specific for all nutrient transporters and the control gene, acidic ribosomal 
protein, (FOR: CAACCCAGCTCTGGAGAAAC; REV: 
GTGAGGTCCTCCTTGGTGAA with 100% efficiency) were designed using 
Biology Work Bench (http://workbench.sdsc.edu/) and synthesized (Table 4; 
Integrated Diagnostics Systems, Coralville, IA).  All primer sets were optimized 
(all reactions were annealed at 58.7 °C) using a pooled RNA sample which was 
created by combining RNA from both treatment groups.  The efficiency (E) of  
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Gene System 
Name 
Substance 
Transported 
Primer Sequence Efficiency
FOR: TTTTTATCGGAGGGTTGCTG EAAT-1 
(SLC1A3) 
XAG- Anionic Amino 
Acids (GLU, 
ASP) REV: ATCTGGTAACGCGTTTGTCC 
82% 
FOR: GGCTTACTCTCTGGTGGCTG EAAT-3 
(SLC1A1) 
XAG- Anionic Amino 
Acids (GLU, 
ASP) REV: TGCTGCTCACCAACTCATTC 
87% 
FOR: TACTTCCTTGGGGTCTGGTG LAT-1 
(SLC7A5) 
L Neutral Amino 
Acids (LEU, 
ILE, VAL, TYR, 
PHE, MET) 
REV: TCTGGTCGCTTACGTCTCCT 
99% 
FOR: CACCAGCGACATATACACGC LAT-2 
(SLC7A8) 
L Neutral Amino 
Acids (LEU, 
ILE, VAL, TYR, 
PHE, MET) 
REV: CTTAATGGGGCGATTGATGT 
83% 
FOR: TCAACCAGCCTCCTAGCACT CAT-1 
(SLC7A1) 
y+ Cationic Amino 
Acids 
REV: AGGCAGAGCCCATGAGTAGA 
97% 
FOR: AGTGCTCCATTGGGTGAAAC SNAT-2 
(SLC38A2) 
A Neutral Amino 
Acids (ALA, 
SER, PRO, 
GLN) 
REV: CCGTCTTCTCACTGCCTTTC 
95% 
FOR: AACTGTGCGGACCCTATGTC GLUT-1 
(SLC2A1) 
Glucose 
REV: GTCACTTTGGCTTGCTCCTC 
102% 
FOR: CTGAGATGGAGGGATTGCAT GLUT-3 
(SLC2A3) 
Glucose 
REV: TGAAGAGCCCAGTCTCCACT 
91% 
TABLE 4. Nutrient transporter primer sequences and the efficiency for each 
primer set.  
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each primer set was determined utilizing this pool prior to assaying any samples, 
and was used to standardize the target gene ratio.  The efficiency of amplification 
was determined by raising 10 to the power of (-1/slope), for which the slope was 
obtained by plotting the log of the concentration of cDNA against the critical 
threshold (Ct) values (Koch et al., 2007). 
 The PCR reaction contained 25 µl of iQ SYBR green supermix (Bio-Rad 
Laboratories), 2 µl of cDNA diluted to 1:2, and 3 µl each of 5 µM forward and 
reverse primer and 17 µl of water to reach a final reaction volume of 50 µl for 
GLUT-1, GLUT-2, LAT-2, EAAT-1 and EAAT-3 or 3 µl of cDNA diluted 1:2 and 3 
µl each of 5 µM forward and reverse primer and 16 µl of water to reach a final 
reaction volume of 50 µl for CAT-1, SNAT-2 and LAT-1.  A single product per 
amplification was determined by examining both the melting curve and by a 1.5% 
agarose gel with ethidium bromide.  The expression of each gene is reported as 
a ratio (ratio = [E∆Ct target gene (pool-sample)/ E∆Ct control gene (pool-sample)]) which was 
previously described by Koch et al. (2007). 
 
Statistical Analysis 
 The main effect of growth hormone treatment, day and the treatment by 
day interaction on the cotyledonary expression of GLUT-1, GLUT-3, EAAT-1, 
EAAT-3, LAT-1, LAT-2, CAT-1, SNAT-2 was analyzed by analysis of variance, 
utilizing the general linear models procedure in SAS.  The correlation between 
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nutrient transporters, body weight and crown-rump length of the fetus were 
determined using the correlation procedures of SAS. 
 
Results 
 Periconceptional treatment of ewes with GH did not alter the expression of 
either GLUT-1 or GLUT-3 (0.52 ± 0.08; 0.78 ± 0.11) in the placenta.  However, 
expression of GLUT-3 was greater (p < 0.05) on day 140 compared to day 80 
(Figure 7).   
 Periconceptional treatment of ewes with GH altered the expression of 
EAAT-1 and EAAT-3.  The expression of EAAT-1 increased (p < 0.05) in the 
control group from day 80 to 140 of gestation.  However, the GH treated group 
had similar expression on day 80 and 140 of gestation, which was similar to the 
expression of the control group on day 140 (Figure 8).  A similar pattern of 
expression was observed for EAAT-3 in that expression in the control group was 
greater (p < 0.05) on day 140 than day 80.  However, the GH group had an 
elevated expression on day 80 compared to the controls and maintained the 
same level of expression on day 140 (Figure 9). 
 Expression of the other amino acid transporters that were studied 
including CAT-1, SNAT-2 and LAT-2 were not affected by GH treatment, but had 
an increase (p < 0.05) in expression from day 80 to day 140 (Figure 10, 11, and 
12).  The expression of LAT-1 was not affected by treatment or day (1.18 ± 0.09). 
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 A positive correlation between fetal weight and GLUT-3 (r = 0.49, p < 
0.05), EAAT-3 (r = 0.49, p < 0.05) and SNAT-2 (r = 0.41, p < 0.05) was observed.  
Similarly a positive correlation was detected between crown-rump length and 
EAAT-3 (r = 0.35, p < 0.05) and LAT-1 (r = 0.38, p < 0.05). 
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FIGURE 8. The expression of GLUT-3 in cotyledonary tissue collected on day 80 
and 140 of gestation.  * Indicates a difference between days (p < 0.05).
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Figure 9. Expression of EAAT-1 in cotyledonary tissue collected on day 80 and 
140 of gestation from conceptuses gestated by control ewes or ewes treated with 
sustained release growth hormone at breeding.  Means with different letters differ 
(p < 0.05). 
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Figure 10. Expression of EAAT-3 in cotyledonary tissue collected on day 80 and 
140 of gestation from conceptuses gestated by control ewes or ewes treated with 
sustained release growth hormone at breeding.  Means with different letters differ 
(p < 0.05).
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Figure 11. The expression of CAT-1 in cotyledonary tissue collected on day 80 
and 140 of gestation.  * Indicates a difference between days (p < 0.05). 
* 
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Figure 12. The expression of SNAT-2 in cotyledonary tissue collected on day 80 
and 140 of gestation.  * Indicates a difference between days (p < .05). 
        * 
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Figure 13. The expression of LAT-2 in cotyledonary tissue collected on day 80 
and 140 of gestation.  * Indicates a difference between days (p < 0.05). 
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Discussion 
 Cotyledonary expression of GLUT-3 increased from day 80 to 140 of 
gestation and was positively correlated with fetal weight.  However, no difference 
in the expression of GLUT-1 was observed in this experiment.  Glucose is 
essential to the fetus because it is the primary substrate for fetal energy and 
metabolism and is passively transferred from maternal circulation to the fetal 
circulation by a concentration-dependent mechanism via sodium independent 
transporters GLUT-1 and GLUT-3 (Robertson and Karp, 1976; Jansson et al., 
1993; Bell et al. 1999; Limesand et al., 2004; Wooding et al., 2005).   
 The increase in GLUT-3 mRNA expression with an increase in gestational 
age observed in this experiment is similar to previous data in which total 
placental mRNA expression continued to increase as the day of gestation 
increased (Currie et al., 1997; Ehrhardt and Bell, 1997).  The expression of 
GLUT-1 in this experiment is similar to the expression data observed by Currie 
and coworkers (1997) in which GLUT-1 expression did not increase between day 
60 and 140 of gestation.  However, Ehrhardt and Bell (1997) using twin 
pregnancy and northern blotting, reported an increase in GLUT-1 expression 
from day 75 to 140.  The magnitude of change in GLUT-1 expression observed 
by Ehrhardt and Bell (1997) was relatively small (1.8 times), compared to the 
change in GLUT-3 expression (3.9 times).  Data available on for GLUT-1 
expression is not consistent and may vary because of fetal number or the 
methodology used to determine expression. 
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 The majority of information available on amino acid transporters in the 
placenta comes from human studies and has been reviewed in great detail 
(Roberston et al., 1976; McGivan and Pastor-Anglada, 1994; Jansson, 2001; 
Kudo and Boyd, 2001; Regnault).  However, what information is available on 
amino acid transport in the sheep is limited to uptake of nonmetabolizable amino 
acids, or amino acid flux into fetal circulation, from chronically instrumented 
fetuses, and not on transporter expression or location (Lemons et al., 1976; 
Jozwik et al., 2004; Vrijer Kwon et al., 2004; et al., 2004). 
 Nutrients have to be in sufficient supply and delivered to the developing 
fetus in a timely fashion for proper growth and development.  In the last third of 
gestation, a period in which fetal growth increases exponentially limiting fetal 
nutrient availability, has been directly linked to intrauterine growth restriction and 
long term alterations in organ function.  The mechanisms by which this occurs 
includes a decrease in maternally derived nutrients or insufficient transport of 
nutrients across the placenta (Barker 1995; Ravelli et al. 1999; Godfrey & Barker 
2000; Jensen et al. 2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al. 
2005; Wu et al. 2006).  Until recently, investigators have suggested that limiting 
nutrient availability was the cause of fetal growth restriction; however, recent 
evidence suggests that if the number of transporters is limited, no matter what 
the nutrient availability is, intrauterine growth restriction occurs (Jansson et al., 
2006). 
 Cotyledonary expression for both EAAT-1 and EAAT-3 was affected by 
treatment and day.  The expression for both EAAT-1 and EAAT-3 increased from 
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day 80 to 140 of gestation in the control group.  However, GH treatment led to an 
increased expression of both transporters on day 80 of gestation, which was 
similar to the expression observed on day 140.  The elevated expression 
observed on day 80 of gestation in the growth hormone group may be just one 
reason why lambs are larger at birth.  This information further supports the 
concept that growth hormone alters placental efficiency.  As previously reported, 
placental efficiency as measured by fetal weight divided by chorioallantoic weight 
is greater on day 80 of gestation in ewes that were treated with growth hormone 
at breeding (Costine et al., 2005).  The increase in EAAT-1 and EAAT-3 on day 
80, which is similar the level of expression on day 140 in the controls, may be 
just one mechanism by which these placentas are capable of transporting more 
nutrients compared to control placenta and therefore more efficient. 
 Cotyledonary expression of CAT-1, SNAT-2, LAT-1 and LAT-2 were not 
altered by growth hormone treatment at breeding.  However, expression of all of 
the transporters, except LAT-1, increased from day 80 to 140 of gestation.  This 
observation is not surprising in that as fetal growth rate increases the amount of 
nutrients required to support growth increases as well.  Therefore, an increase in 
transporter number may occur just to meet fetal nutrient demands. 
 In conclusion, growth hormone treatment at breeding increases 
cotyledonary expression of EAAT-1 and EAAT-3 in the sheep at midgestation, 
which is maintained throughout the rest of gestation.  While this is only one 
transporter, it may give further insight into a possible mechanism by which 
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growth hormone treatment to the ewe at breeding leads to a more efficient 
placenta during gestation and therefore, larger lambs at birth. 
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Abstract 
 Altering the fetal environment can modify the composition or growth rate of 
the fetus, a concept known as fetal programming.  A majority of the research in 
this area has focused on intrauterine growth restriction (IUGR), which has been 
linked to adult diseases.  A few studies have attempted to ameliorate the 
negative effects of IUGR, by applying growth promoters late in gestation.  The 
objective of this study was to determine the effects of a single treatment of 
sustained release growth hormone given during the periconceptional period on 
fetal growth and development.  Ewes assigned to treatment received 500 mg of 
sustained release growth hormone.  Birth weight, crown-rump length and 
abdominal girth were determined and a serum sample collected to determine 
IGF-I concentrations in all lambs.  In a subset of male lambs, liver, heart and 
brain weights, as well as left and right ventricular wall thickness and liver IGF-I 
and growth hormone receptor mRNA expression were determined.  On postnatal 
day 100 a subset of ewe lambs were weighed and challenged with growth 
hormone releasing hormone to assess the functionality of the growth hormone 
axis.  Lambs from treated ewes had increased birth weight and abdominal girth 
compared to control lambs; however, there was no difference in crown-rump 
length.  Hepatic mRNA expression of growth hormone receptor was increased, 
and IGF-I tended to increase, in lambs gestated by growth hormone treated ewes 
compared to controls.  The left ventricular wall was thinner from lambs in the 
growth hormone treated group compared to controls.  On postnatal day 100, 
those ewe lambs born to ewes treated with growth hormone were heavier and 
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had a reduced IGF-I response to growth hormone releasing hormone challenge.  
In conclusion, treating ewes with sustained release growth hormone not only 
increased lamb birth weight but also resulted in alteration in lamb growth and 
altered growth hormone axis. 
Key Words: growth hormone, fetal growth, GHRH challenge
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Introduction 
 The concept of “fetal programming” is described as any stimulus, either 
positive or negative, that occurs in utero which has a permanent affect and alters 
the physiology of the offspring (Armitage et al., 2004).  The list of systems in 
which fetal programming has been found to impact is lengthy and includes the 
cardiovascular, respiratory, endocrine, reproductive, central nervous, skeletal 
and immune systems as well as kidney and liver function (Godfrey & Barker 
2000; Wu et al., 2004).  The observation that adult onset diseases are directly 
linked to fetal programming has brought about investigations of a number of 
animal models in an attempt to mimic the pathophysiology observed in humans 
(Wallace et al., 2005; Wu et al., 2006). 
 Models developed to date to investigate fetal programming exclusively 
induce intrauterine growth restriction (IUGR).  Intrauterine growth restriction is an 
alteration in the uterine environment at any time point during gestation that is 
detrimental to the growth and development of the fetus.  The methods for 
inducing IUGR can involve maternal dietary manipulation and/or induction of 
placental insufficiency (Armitage et al., 2004; Wu et al., 2006).  Maternal dietary 
manipulation includes a range of approaches from nutrient restriction to 
overnourishing adolescent ewes.  Both models result in decreased nutrient 
availability to the developing fetus, but the overnourished adolescent ewe model 
appears to induce IUGR by reducing placental efficiency (Armitage et al., 2004; 
Wallace et al., 2005; Wu et al., 2006).  In addition to the overnourished 
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adolescent ewe, other placental insufficiency models alter the placenta’s ability to 
transport nutrients to the fetus and include, uterine artery ligation, placental 
embolism, carunclectomy and maternal hyperthermia (Bell et al., 1989; Thureen 
et al., 1992; Regnault et al., 2003; Amitage et al., 2004; Wallace et al., 2004; 
Louey et al., 2005). 
 Many models that lead to IUGR have been studied in detail, and the 
specific alterations in fetal physiology that result from the environmental insult are 
well documented.  However, only a few studies have tried to ameliorate the 
impact of experimentally induced IUGR by administering growth promoters.  The 
limited number of studies that have attempted to attenuate the negative impact 
on fetal physiology have examined growth hormone treatment to the dam or 
infusing the fetus directly with growth hormone or insulin like growth factor (IGF; 
Harding et al., 1997; Bauer et al., 2003; Wallace et al., 2004; Wallace et al., 
2006).  In these studies the effects of growth hormone, given during either mid or 
late gestation, only appear to have a transient effect (i.e., they were not able to 
overcome the negative impact IUGR had on growth and development of the 
offspring).  
 Few researchers have attempted to promote fetal growth and 
development under normal uterine conditions.  Growth hormone administered to 
either the fetus or the dam, late in gestation under normal gestational conditions, 
did not alter fetal growth and development (Stelwagen et al., 1994; Bauer et al., 
2000).  However, these experiments may have two potential flaws.  First growth 
hormone is not the primary stimulator for growth during fetal development 
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because hepatic growth hormone receptors are in very low abundance and do 
not appear to stimulate the secretion of IGF, which is the primary growth 
promoter (Gluckman and Pinal, 2003).  Second, growth hormone was 
administered following the majority of placental growth and altering placental 
development may limit fetal growth because it regulates the nutrient supply.  In 
sheep, placental size increases exponentially until day 80, and from that point, 
further development is mainly due to increased vascular complexity (Reynolds et 
al., 2005a; Reynolds et al., 2005b; Borowicz et al., 2007).  Recently we have 
shown that a single injection of sustained release growth hormone administered 
at breeding altered the uterine environment at day seven of gestation and 
increased birth weight by 10% (Costine et al., 2005).  At day 80 of gestation, 
placental mass in the growth hormone group was lower than controls, but by day 
140 both had similar placental weights (Costine et al., 2005).  Comparing the 
results of experiments in which growth hormone was administrated in mid or late 
gestation with that at the time of breeding has led us to suggest that early growth 
hormone administration alters the uterine environment during a developmental 
window in which the embryo, including the trophectoderm (which will become the 
outer layer of the fetal placenta), and in inner cell mass (which will become the 
embryo proper and later fetus and contribute to the placenta) can be altered. 
 Therefore, the objective of the current study was to determine how a 
single injection of sustained release growth hormone, given immediately prior to 
conception, alters: 1) fetal growth and development 2) postnatal growth and 
development of the growth hormone axis.   
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Materials and Methods 
 Ewes (n=50), primarily of rambouillet breeding, from the West Virginia 
University farm were used for the experiment.  All procedures were approved by 
the West Virginia University Animal Care and Use Committee (ACUC No. 03-
1012).   
 Estrus was synchronized by administering 20 mg of prostaglandin F2α 
(Lutalyse, Pfizer) on day 0 and a second injection of prostaglandin F2α on day 8.  
Ewes were randomly assigned to either a control group (n=27) or a growth 
hormone treated group (n=23).  The growth hormone treated group received a 
single 500 mg injection of sustained release recombinant bovine growth hormone 
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the same time as the 
second prostaglandin F2α injection.  This dose was previously reported to 
increase uterine luminal insulin like growth factor-I (IGF-I) on day 7 of gestation 
and result in larger lambs at birth (Costine et al., 2005).  Following the second 
injection of prostaglandin F2α, ewes were penned with a fertile ram.  At term, all 
lambs (n=84) born alive were processed shortly after birth (average gestation 
was 145 days).   
 
Lamb Data 
 Shortly following birth, and before nursing, all lambs were processed.  
Each lamb was weighed, measured for crown-rump length, abdominal girth and 
crown width and a blood sample was collected for IGF-I concentration.  A subset 
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of males (n=22) were further processed for tissue collection.  Each male was 
euthanized with an intravenous overdose of sodium pentobarbital (1.5g, Sigma, 
St. Louis, MO).  The liver was removed, weighed and a portion was snap frozen 
in liquid nitrogen for further analysis of hepatic expression of growth hormone 
receptor and IGF-I.  The heart was removed and weighed before the ventricles 
were separated from the atria and fixed in 10% formalin.  Following fixation the 
right and left ventricular wall thickness was determined using calipers.  The brain 
was also removed from the skull to determine brain weight. 
 
Growth Hormone Releasing Hormone Challenge 
 A subset of ewe lambs (n=14) were weighed at 100 days-of-age and a 
blood sample was collected (0 min).  The lambs were then subjected to a growth 
hormone releasing hormone challenge (3 µg/kg body weight; GHRH factor-29; 
Simga, St. Louis, MO; Suttie et al., 1991) and blood samples were collected 10, 
20, 30, 45, 60 and 90 min following challenge. 
 
Insulin Like Growth Factor-I  
 The concentration of IGF-I in plasma was determined using a 
commercially available Enzyme-Linked ImmunoSorbent Assay, previously 
validated in our laboratory (Diagnostic Systems Laboratories Inc., Webster, TX; 
Costine et al.,, 2005).  Briefly, this assay utilizes two antibodies in a sandwich-
type immunoassay. The enzyme horseradish peroxidase is linked to the 
secondary antibody and in the presence of tetramethylbenzidine, a substrate for 
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horseradish peroxidase, the absorbance is directly proportional to the 
concentration of IGF-I. 
 
Gene Expression 
 Liver RNA was extracted using TRIzol as described by Koch et al. (2007).  
This procedure includes two back extractions against acid phenol:chloroform 
(5:1; pH=4.5; Ambion, Austin, TX) followed by two back extractions against 
phenol:chloroform: isoamyl alcohol (25:24:1; pH=6.6) to remove additional 
proteins, DNA and lipids.  The RNA was reconstituted in 40 µl of nuclease free 
water and the concentration was determined spectrophotometrically at 260 nm.  
The quality of RNA was determined by the appearance of bands corresponding 
to 28S and 18S rRNA and a distribution of mRNA of high molecular weight on a 
3% agarose gel with ethidium bromide.  Complementary DNA (cDNA) was 
synthesized from 2 µg of RNA which was reverse transcribed using random 
hexamers and Moloney Murine Leukaemia Virus reverse transcriptase 
(Promega, Madison, WI).  Real-Time RT PCR (iCycler, Bio-Rad Laboratories, 
Hercules, CA) was utilized to quantify the abundance of cDNA as previously 
described (Koch et al., 2007).  Primers specific for growth hormone receptor, 
IGF-I and acidic ribosomal protein (which was used as a control gene), were 
designed using Biology Work Bench (http://workbench.sdsc.edu/) and 
synthesized (Integrated Diagnostics Systems, Coralville, IA).  Primers for growth 
hormone receptor (forward CATGTCACTGGACAGATGGG; reverse 
TGTTTTCACCAGCAGAGACG), IGF-I (forward GCCAAAACGGTCAAAGGTGA; 
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reverse AGGCATAATTGGGGAGCTTT) and acid ribosomal protein (forward 
CAACCCAGCTCTGGAGAAAC; reverse GTGAGGTCCTCCTTGGTGAA) were 
optimized (all reactions were annealed at 58.7 °C) using a pooled RNA sample 
which was created by combining RNA from both treatment groups.  The 
efficiency (E) of each primer set was determined utilizing this pool prior to 
assaying any samples, and was used to standardize the target gene ratio.  The 
efficiency of amplification was determined by raising 10 to the power of (-
1/slope), for which the slope was obtained by plotting the log of the concentration 
of cDNA against the critical threshold (Ct) values (Koch et al., 2007).  Efficiencies 
for growth hormone receptor, IGF-I and acid ribosomal protein were 1.84, 1.85 
and 1.94, (i.e., 92%, 93% and 97% theoretical yield) respectively.   
 Each PCR reaction contained 25 µl of iQ SYBR green supermix (Bio-Rad 
Laboratories), 2 µl of cDNA diluted to 1:2, and 3 µl each of 5 µM forward and 
reverse primer and 17 µl of water to reach a final reaction volume of 50 µl.  A 
single product per amplification was determined by examining both the melting 
curve and by a 1.5% agarose gel with ethidium bromide.  The expression of each 
gene is reported as a ratio (ratio = [E∆Ct target gene (pool-sample)/ E∆Ct control gene (pool-
sample)]) previously described by Koch et al. (2007). 
 
Statistical Analysis 
 The effect of growth hormone treatment to the dam during the 
periconceptional period on lamb birth weight, crown-rump length, abdominal 
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girth, crown width, IGF-I concentration, brain weight, right and left ventricular wall 
thickness and hepatic expression of IGF-I and growth hormone receptor was 
analyzed by analysis of variance, utilizing the general linear models procedure in 
SAS.  The effect of GH treatment to the dam on IGF-I concentrations following 
GHRH challenge was analyzed by repeated measures ANOVA utilizing the 
mixed models procedure in SAS.  The relationships among variables were 
determined by the correlation procedure of SAS.   Insulin like growth factor-I 
concentrations following growth hormone releasing hormone challenge were 
analyzed by repeated measures ANOVA.   
 
Results 
 Both weight and abdominal girth at birth were greater (P < 0.05) in the 
group of lambs born to ewes treated with growth hormone compared to those 
born to control ewes (Figure 13a and 13b).  However, no difference in crown-
rump length (48.51 ± 1.44 cm; P > 0.05; Figure 13c) or crown width (8.82 ± 0.20 
cm) was detected. 
 The thickness of the left ventricular wall at birth was decreased (P < 0.05) 
in male lambs born to ewes treated with growth hormone compared to male 
lambs born to control ewes (Figure 14).  However, no difference in the thickness 
of the right ventricular wall was detected (Figure 14).  No difference in heart 
weight at birth was detected between the control and growth hormone groups 
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(34.7 ± 2.1 g; p > 0.05).  Brain weights were also not different (50.4 ± 2.1 g; p > 
0.05). 
 Relative expression of growth hormone receptor was increased (p < 0.05) 
in liver tissue of male lambs born to ewes treated with growth hormone compared 
to control (Figure 15).  Similarly, there was a trend (p = 0.06) for an increase in 
IGF-I expression in the growth hormone group compared to controls (Figure 15).  
However, liver weight at birth was not different between control male lambs and 
male lambs born to ewes treated with growth hormone at breeding (108.9 ± 5.1 
g; p > 0.05).  Plasma IGF-I at birth was not different in lambs from either 
treatment group (38 ± 6.6 pM).  However, there was a positive correlation 
(r=0.48; p < 0.05) between birth weight and IGF-I concentration. 
 On postnatal day 100, ewe lambs born to ewes treated with growth 
hormone where still 20% heavier than those born to control ewes (Figure 16).  
Ewe lambs born to dams treated with growth hormone had a reduced IGF-I 
response following the growth hormone releasing hormone challenge on day 100 
(Figure 17). 
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FIGURE 14. Birth data of lambs born to control ewes and ewes treated with 
sustained release growth hormone at breeding a) birth weight b) abdominal girth 
c) crown-rump length.  *Indicates that treatment means differ (p < 0.05). 
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FIGURE 15. Ventricular wall thicknesses of fetal hearts in ram lambs born to 
control ewes and ewes treated with sustained release growth hormone at 
breeding.  *Indicates that treatment means differ (p < 0.05).
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FIGURE 16. Neonatal hepatic mRNA expression of IGF-I and growth hormone 
receptor from ram lambs born to control ewes and ewes treated with sustained 
release growth hormone at breeding.  *Indicates that treatment means differ (p < 
0.05).  †Indicates that treatment means tend to differ (p = 0.06).
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FIGURE 17. Weight of ewe lambs at postnatal day 100 that were either born to 
control ewes or ewes treated with growth hormone.  *Indicates that treatment 
means differ (p < 0.05).
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FIGURE 18. Pattern of secretion of IGF-I following growth hormone releasing 
hormone challenge on postnatal day 100 by ewe lambs born to control ewes and 
ewes treated with sustained release growth hormone at breeding.  *Indicates that 
treatment means differ (p < 0.05). 
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Discussion 
 Administering a single injection of sustained release growth hormone prior 
to breeding alters fetal growth and development of lambs.  Lambs born to ewes 
treated with growth hormone at breeding are 25% heavier at birth compared to 
controls.  Lambs in the growth hormone group appear to have an altered 
composition, as indicated by the observed increased abdominal circumference 
without a difference in crown-rump length, leading us to suggest that the stature 
of the growth hormone group is unaltered.   
 The increase in birth weight of lambs born to ewes treated with growth 
hormone in the current experiment is in agreement with those found previously in 
which 500 mg of sustained release growth hormone given at the time of breeding 
increased lamb weight by 10% (Costine et al., 2005), even though in the current 
experiment growth hormone was given at the time of the second prostaglandin 
F2α injection.  In contrast, administration of 0.1 mg/kg growth hormone twice daily 
to the dam for 10 days or once daily for 27 day in late gestation did not affect 
fetal growth (Stelwagen et al., 1994; Harding et al., 1997).   
 Several researchers have attempted to ameliorate the effects of 
intrauterine growth restriction by administering growth hormone during the latter 
portion of fetal development, but to our knowledge only Costine et al. (2005; from 
this laboratory) and the current experiment have administered growth hormone 
during the periconceptional period or in early gestation.  For example, in an 
experiment conducted by Bauer et al. (2003) intrauterine growth restriction was 
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induced by placental embolization on days 110-116 which was followed by direct 
infusion of growth hormone to the fetus at a rate of 3.5 mg/day late in gestation.  
Growth hormone infusion did not alter fetal weight, crown-rump length, chest 
girth or fetal growth rate (Bauer et al., 2003).  Wallace et al. (2004) utilized the 
over-nourished pregnant adolescent ewe model as a means to induce fetal 
growth restriction and examined whether 0.14 mg/kg growth hormone 
administered daily to the dam in mid gestation (i.e., days 35-80) might alter fetal 
development.  In their study, growth hormone treatment appeared to have no 
affect on either fetal weight or umbilical girth (Wallace et al., 2004).  Utilizing the 
same adolescent ewe model, growth hormone was administered late in gestation 
to the dam at a rate of 0.14 mg/kg/day from days 95-125.  At day 130, growth 
hormone treatment appeared to increase fetal weight and girth in the growth 
restricted group making them equivalent to non-growth restricted.  However, at 
birth the effect of growth hormone treatment was no longer observed, leading to 
the suggestion that late in gestation growth hormone treatment only elicits a 
transient response (Wallace et al., 2006).  
 It is not surprising that administration of growth hormone during mid or late 
gestation does not increase fetal growth rate or ameliorate the effects of 
intrauterine growth restriction.  This is because fetal growth is generally limited by 
the ability of the placenta to supply nutrients.  The placenta grows in size during 
the first 80 days of gestation and then for the remainder of gestation it develops a 
larger, more complex vascular network to allow for the increased nutrient 
demand of the rapidly growing fetus (Reynolds et al., 200a; Reynolds et al., 
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200b; Borowicz et al., 2007).  Apparently, growth hormone administration in mid 
to late gestation only temporarily influences placental efficiency. 
 During fetal development, the impact of growth hormone is very minimal 
even though the concentration of growth hormone is 10- to 20-fold higher than 
postnatal levels (Bloomfield et al., 2006).  Growth hormone’s inability to stimulate 
fetal growth has been associated with a lack of growth hormone receptor 
expression.  Growth hormone receptor expression is low during fetal 
development, but is induced by the glucocorticoid surge at parturition and 
remains elevated in lambs (Li et al., 1996; Gluckman & Pinal 2003; Bloomfield et 
al., 2006).  The apparent failure of GH to ameliorate growth restriction should not 
be expected since GH is not the main regulator of fetal growth.   
 Administration of growth hormone during mid gestation to adolescent 
pregnant sheep more than doubled the concentration of glucose in fetal 
circulation, although expression of both glucose transporters found in the 
placenta were not altered (Wallace et al., 2004).  In the uteroplacental embolism 
model, growth hormone administration restored the glucose concentration of the 
intrauterine growth restricted group to control concentrations (Bauer et al., 2003).   
 In the current experiment, growth hormone administration occurred 
immediately prior to breeding.  We have speculated that the observed increase in 
fetal weight and abdominal girth in the current study are a result of altered 
embryo growth that leads to altered placental development and function allowing 
for an increased placental efficiency late in gestation.  This early embryonic 
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programming may be a result of an altered uterine environment which has been 
observed with growth hormone treatment at breeding (Costine et al., 2005).  
Exogenous progesterone administered during embryonic development appears 
to advance the uterine environment and increase fetal growth.  Those embryos 
exposed to an altered uterine environment by early progesterone administration 
had a greater fetal mass and larger crown-rump length compared to controls 
(Keelmann et al., 1994). Similarly embryos that are co-cultured with granulosa 
cells before being returned to the recipient female were 14% heavier by day 61 of 
gestation and 18% larger by day 125 compared to those that were just cultured in 
media and not exposed to granulosa cells (Sinclair et al., 1999). 
 As in the neonate, IGF-I is the major growth factor responsible for fetal 
growth, but the main stimulator for IGF-I secretion in utero is nutrients, not growth 
hormone (Oliver et al., 1996; Bloomfield et al., 2006).  The postnatal drop in 
growth hormone concentration, to that of an adult, is accompanied by an 
increase in both the expression of growth hormone receptor and IGF-I, which 
together lead to growth hormone regulated IGF-I secretion after birth (Fowden, 
1995; Breier et al., 1994). 
 A positive correlation between placental efficiency and fetal IGF-I 
concentrations has previously been observed in ewes treated with sustained 
release growth hormone at breeding (Costine et al., 2005).  The current study 
found that treatment with growth hormone prior to breeding tended to increase 
the hepatic mRNA expression of both IGF-I and growth hormone receptor at 
birth.  The major fetal growth promoter, IGF-I, is mainly regulated by nutrients 
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(Bloomfield et al., 2006).  Fetal expression of IGF-I and growth hormone receptor 
can be influenced by maternal nutrition as well.  A 60% maternal nutrient 
restriction from day 28 to 80 followed by re-feeding to a control level until day 140 
resulted in a decrease in fetal-hepatic IGF-I and growth hormone receptor at day 
80 of gestation.  However, in the nutrient restriction growth that was returned to a 
control diet fetal-hepatic expression of both IGF-I and growth hormone receptor 
were increased by day 140 suggesting regulation by nutrient availability (Brameld 
et al., 2000). 
 Treatment with growth hormone prior to breeding also appeared to alter 
the postnatal growth and development of lambs.  At day 100 following birth lambs 
born to ewes treated with growth hormone were still 20% heavier than lambs 
born to controls.  Ewe lambs born to growth hormone treated ewes also had a 
suppressed response to growth hormone releasing hormone challenge 
compared to controls. 
 Little information has been collected on the effects of growth hormone 
administration during gestation on postnatal development in lambs and more 
specifically how the growth hormone axis of these lambs may be altered.  In the 
current experiment plasma IGF-I levels immediately following birth were not 
different between the treated and control groups.  These results are similar to 
those found by Stelwagen et al., (1994), in which the concentration of IGF-I 
immediately following birth was not different between control lambs and those 
exposed for 27 days to growth hormone late in gestation at a concentration of 0.1 
mg/kg ewe body weight.  In an IUGR environment induced by placental 
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embolization, growth hormone treatment was able to elevate the concentration of 
IGF-I in fetal circulation of the IUGR fetuses but only to control levels (Bauer et 
al., 2003).  These data agree with hepatic expression data, in which growth 
hormone treatment late in gestation increased hepatic growth hormone receptor 
expression, but not IGF-I (Bloomfield et al., 2006).  The current experiment only 
examined hepatic expression in newborn lambs and cannot be directly compared 
to Bloomfield et al., (2006); however, it may be important to note that the 
observed increase in hepatic mRNA expression of growth hormone receptor and 
the trend of an increased IGF-I expression in the growth hormone group may 
indicate an altered growth hormone axis. 
 The current study also determined ventricular wall thickness because 
during fetal development, the heart can undergo adaptive changes to 
compensate for alterations in fetal physiology.  The observed decrease in left 
ventricular wall thickness leads us to suggest that during fetal development those 
offspring gestated by dams treated with growth hormone at breeding have 
reduced peripheral vascular resistance.  In sheep, under normal uterine 
conditions, cardiomyocyte growth is primarily hyperplastic until terminal 
differentiation, with the majority of hypertrophic growth occurring only after birth 
(Burrell et al., 2003).  This pattern of development is changed in models of 
intrauterine growth restriction.  For example, when placental embolization was 
utilized to induce fetal growth restriction late in gestation, an increase in heart 
weight, ventricular wall thickness and the right ventricular cardiomyocyte protein-
to-DNA ratio (i.e., cell size) was observed in growth restricted fetuses compared 
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to controls at day 130 (Murotsuki et al., 1997).  Utilizing the same model, growth 
restriction reduced relative heart weight (when corrected to fetal weight) and 
retarded growth of the left ventricle as measured by a decreased proportion of 
binucleated cardiomyocytes (i.e., inhibited maturation) at day 130 of gestation 
(Bubb et al., 2007).  A different intrauterine growth restriction model, in which 
dams were nutritionally restricted to 50% of the control group from day 28 to day 
78 of gestation, resulted in an increase in ventricular weight per gram of fetal 
body weight (Vonnahme et al., 2003).  A hypertrophic increase in the fetal 
ventricular wall has been suggested to result from an increase in ventricular 
afterload which is indicative of an increase in mean arterial pressure (Samson et 
al., 2000; Vonnahme et al., 2003).  A mechanism in which placental vascular 
resistance may be increased in intrauterine growth restriction resulting in altered 
fetal heart development has been postulated by Vonnahme et al. (2003).  We 
suggest that the reduced left ventricular wall thickness observed in the current 
study is consistent with a decrease in mean arterial pressure in fetuses gestated 
in ewes treated with growth hormone prior to breeding. 
 In conclusion, treating ewes with a single injection of sustained release 
growth hormone prior to breeding alters fetal growth and development.  Lambs 
born to ewes treated with growth hormone are larger, they have a reduced 
ventricular wall thickness (which is indicative of a reduced mean arterial 
pressure) and they have what appear to be alterations in the growth hormone 
axis.  Impacting or programming the early embryo, specifically the developing 
placenta, potentially alters fetal development throughout gestation.  The placenta 
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is responsible for supplying nutrients for proper growth, it influences mean 
arterial pressure which impacts cardiovascular development, and its efficiency 
may directly impact the growth hormone axis.  The current work may stimulate a 
new line of thinking when examining developmental programming of the 
conceptus and how it ultimately alters postnatal growth and development of the 
offspring. 
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